CLINICAL  STUDY  PROTOCOL 
Title: A Phase 3 Multi- Center, Double -Blind, Randomized, Vehicle-Controlled 
Study of S5G4T-1 in the Treatment of  Papulopustular Rosacea 
Protocol No:  SGT-54-01: October 24, 2018 
Protoc
ol Version: 4 
Original Version: 3.0 
Sponsor: Sol-Gel Technologies Ltd. 
7 Golda Meir St. 
Weizmann Science Park  
Ness  Ziona 7403650, Israel  
Confidential  
The information contained in this document is confidential and proprietary property of Sol -Gel Technologies, Inc. The recipient agrees that no  
unpublished  information  contained  herein  will be published or disclosed  without prior  written  approval  of Sol-Gel except  as may be disclosed 
to independent ethics committees/institutional review boards or duly authorized representatives of the US Food and Drug Administration  
under  the condition that  they maintain  confidentiality.  NCT #[STUDY_ID_REMOVED]
Sc"f-s4-i,1. Ver4.0
2. PROTOCOL APPROVAL- SPONSOR STGNATURE PAGE
protocolTitle: A Phase 3 Multi-Center. Double-Blind, Randomized. Vehicle-Controlled
Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Study Products: S5C4T-I compared to Vehicle
Sol-Cel Technologies Ltd. commits to conduct the study as described herein in accordance with
the currenr lnternational Conference on Harmonization (lCH) - Good Clinical hactices (cGCPs)
and the World Medical Association Declaration of Helsinki and in compliance with the obligations
and requiremenrs of the Sppnsor as listed in 2l CFR Part 312. The following individuals approve
the Ociober 24, 2018 u"rli6n of the SGT-54-01 protocol. All changes to this version of the
protocol must have pribr written approval and require an amendment or administrative letter.
$ponsor Rcprcsentative:
    
Sol-Gel Technolog,ies Ltd.
7 Golda Meir St.
Weizmann Science Park
Ness Ziona ?403650. lsrael
Signaturt: 
l,lovember 8,2018
Biosletistics end Detr Managcment:
 
   
QST Consultations, l.td.
| 1275 Edgervater Dr.
Allendale. Ml 49401
Signature:
Date:Medlcrl Monitor:
  
 
Symbio. l.l..C
?l Penl'St.'
Port Jetlbrson. NY I 1777
Date:Signature:
I)atel
CONFIDENTI.AI-Page 2 ofE5

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  3 of 85  
 3. INVESTIGATOR  PROTOCOL  ACKNOWLEDGMENT 
Protocol Title: A Phase 3 Multi -Center, Double -Blind, Randomized, Vehicle -Controlled 
Study of S5G4T-1 in the Treatment of Papulopustular Rosacea  
Study Products:     S5G4T -1 compared to Vehicle 
I have read this protocol and commit to conduct the study as outlined herein, in accordance with 
the current International Conference on Harmonization (ICH) current Good Clinical Practices  
(cGCPs) and the World Medical Association Declaration of Helsinki and complying with the  
obligations and requirements  of clinical  investigator(s) and all other requirements as listed  in 
21 CFR Part 312 and all other applicable regulations. Any deviations will be agreed to by prior  
discussion between the Sponsor/Contract Rese arch Organization (CRO) and me.  
I am thoroughly familiar with the appropriate use of the investigational products(s), as described  
in this protocol, and any other information  provided by the sponsor or designee,  including, but not 
limited  to, the current  Investigator Brochure (or equivalent  document). I agree to provide sufficient  
time,  and adequate numbers of qualified  staff and facilities  for the foreseen  duration of the clinical  
study to conduct the study  properly, ethically and safely.  
I agree to completely  inform  all Patients  in this study concerning the pertinent  details  and purpose 
of the study prior to their agreement to participate in the study in accordance with cGCPs and regulatory authority requirements. I will be responsible for m aintaining each Patient’s consent  
form  in the study file and providing each Patient  with a  copy of the signed consent form. 
 
 
 
Investigator’s  Signature   Date  
Investigator’s  Printed  Name    
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  4 of 85  
 4. TABLE  OF CONTENTS  
2. PROTOCOL  APPROVAL  – SPONSOR SIGNATURE PAGE  .............................................. 2 
3. INVESTIGATOR  PROTOCOL  ACKNOWLEDGMENT  ...................................................... 3 
4. TABLE OF  CONTENTS  ......................................................................................................... 4 
5. PROTOCOL  SYNOPSIS  ......................................................................................................... 9 
5.1. Synopsis ........................................................................................................................ 9 
5.2. Study Flow  Chart  ........................................................................................................21 
6. LIST  OF ABBREVIATIONS AND TERMS  .........................................................................22 
7. INTRODUCTION AND BACKGROUND  ...........................................................................24 
8. OBJECTIVE  ...........................................................................................................................26 
9. ETHICS  ..................................................................................................................................28 
10. INSTITUTIONAL  REVIEW BOARD  (IRB) AND INFORMED CONSENT  .....................29 
11. OVERALL  STUDY DESIGN  ................................................................................................30 
12. STUDY POPULATION  .........................................................................................................31 
12.1. Randomization and Blinding ......................................................................................31 
12.2. Inclusion Criteria  ........................................................................................................32 
12.3. Exclusi on Criteria  .......................................................................................................33 
12.4. Prohibited, Previous and Concomitant Therapies ......................................................35 
12.5. Precautions  ..................................................................................................................36 
13. STUDY PROCEDURES  ........................................................................................................38 
13.1. St
udy Patient  Identification  ........................................................................................38 
13.2. Screen  Failure and Discontinuation Criteria ...............................................................38 
13.3. Patient  Screening  and Enrollment ...............................................................................39 
13.4. Assignment of Randomization ...................................................................................39 
13.5. Demographics/Medical  History  ..................................................................................39 
13.6. Concomitant Medications  ...........................................................................................39 
13.7. Physical  Examination  .................................................................................................39 
13.8. Urine  Pregnancy  Test ..................................................................................................40 
13.9. Study Flow  Chart  ........................................................................................................41 
13.10. Screening  Visit (Visit 1) .............................................................................................42 
13.11. Baseline Visit (Visit 2, Day 1) ....................................................................................42 
13.12. On treatment (Visit 3) – Week 2, Day  15 (± 3 days)  ..................................................43 
13.13. On-treatment  Visits (Visits 4 and  5) – Weeks 4  and 8, Days  29 and 57  
(± 3 days) ....................................................................................................................44 
13.14. On-tr
eatment  (Visit 6) – Week 12,  Day  85 (± 4  days) or End of Treatment  or 
Early  Termination  .......................................................................................................44 
14. CLINICAL  OUTCOME  ASSESSMENTS  ............................................................................46 
14.1. Investigator Global Assessment (IGA)  .......................................................................46 
14.2. Inflammatory  Lesion Counts ......................................................................................47 
14.3. Er
ythema Severity  Assessments .................................................................................47 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  5 of 85  
 14.4. Telangiectasia Assessment  .........................................................................................47 
14.5. Patient  Reported Outcomes (PRO) .............................................................................48 
14.6. Rosacea Quality  of Life (RosaQoL) ...........................................................................49 
15. PHOTOGRAPHY ...................................................................................................................51 
16. SAFETY  EVALUATIONS  ....................................................................................................52 
16.1. Cutaneous Safety  Assessments ...................................................................................52 
16.2. Local Tolerability  Assessments ..................................................................................53 
17. ADVERSE  EVENTS  ..............................................................................................................54 
17.1. Departure from the Protocol for Individual Patients ..................................................54 
17.2. Definitions  ..................................................................................................................54 
17.3. Causal  Relationship to Study product .........................................................................55 
17.4. Eliciting  and Reporting of Adverse Events ................................................................55 
17.5. Expedited Reporting Responsibilities of  the Study Center .........................................56 
17.6. Submitting  an Expedited Safety  Report to the IRB ....................................................56 
17.7. SAE  & AEs Requiring Discontinuation of Study Drug, including Pregnancies  ........57 
17.8. Pregnancy  ...................................................................................................................57 
17.9. Post Study Adverse Events  .........................................................................................58 
17.9.1. Non-serious Adverse Events  ...........................................................................58 
17.9.2. Serious Adverse Events ..................................................................................58 
18. ST
UDY PRODUCTS / CLINICAL  SUPPLIES  ....................................................................59 
18.1. Method of Treatment  Assignment ..............................................................................59 
18.2. Formulations ...............................................................................................................59 
18.3. Study Products Packaging and Labeling .....................................................................59 
18.4. Preparation,  Dispensing and Storage Instructions ......................................................61 
18.5. Dosing Instructions .....................................................................................................61 
18.6. Study Product Accountability and Study Records  at Sites  .........................................62 
18.7. Return  and Destruction of Study Product Supplies ....................................................62 
18.8. Additional Supplies Provided by Sponsor ..................................................................62 
19. STATISTICAL  CONSIDERATIONS  ...................................................................................63 
19.1. General  Statistical Methods  ........................................................................................63 
19.1.1. Patient  Disposition  ..........................................................................................63 
19.1.2. Demographics and Baseline Characteristics  ...................................................63 
19.1.3. Protocol Deviations ........................................................................................63 
19.1.4. Ana
lysis Populations ......................................................................................63 
19.2. Study Product Evaluations and Analyses ...................................................................64 
19.3. Assessment  of Efficacy  ...............................................................................................65 
19.3.1. Primary  Efficacy  .............................................................................................65 
19.3.2. Secondary  Efficacy  .........................................................................................65 
19.3.3. Supportive Efficacy  ........................................................................................65 
19.4. Sta
tistica l Hypothesis Testing .....................................................................................66 
19.4.1. Test of Superiority for Lesion Count Variables .............................................66 
19.4.2. Test of Superiority for IGA  ............................................................................66 
19.4.3. Test of  Superiority for Secondary Efficacy  and Control of Multiplicity  ........66 
19.4.4. Supportive Efficacy  Analyses  .........................................................................67 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  6 of 85  
 19.4.5. Exploratory Endpoint ......................................................................................67 
19.4.6. Pooling Analysis .............................................................................................68 
19.4.7. Missing  Efficacy  Data Imputations ................................................................69 
19.4.7.1. Lesion  Count Variable Missing Data Imputation  ..........................69 
19.4.7.2. IGA Missing  Data Imputation .......................................................70 
19.4.8. Sensitivity  Efficacy  Analyses  .........................................................................71 
19.4.8.1. Sensitivity  Analyses for Absolute Change in  Lesion Count ..........71 
19.4.8.2. Sensitivity  Analyses for IGA  .........................................................71 
19.4.9. Subgroup Analyses  .........................................................................................72 
19.5. Assessment of Safety  ..................................................................................................72 
19.6. Adverse Events ...........................................................................................................72 
19.6.1. Vital Sign Measurements  ................................................................................73 
19.6.2. Concomitant Medications  ...............................................................................73 
19.7. Sample  Size Determination  ........................................................................................73 
20. ADMINISTRATIVE  CONSIDERATIONS  ..........................................................................74 
20.1. Protocol Compliance ..................................................................................................74 
20.2. Protocol Revisions ......................................................................................................74 
20.3. Protocol Monitoring ....................................................................................................74 
20.4. Required Study Documents ........................................................................................74 
20.5. Electronic  Case Report Forms (eCRF)/Source  Documents ........................................75 
20.6. Re
ports to the IRB/Ethics Committee  (EC) ................................................................75 
20.7. Quality  Assurance Audits ...........................................................................................75 
20.8. Records  Retention  .......................................................................................................75 
21. REFERENCES  .......................................................................................................................76 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  7 of 85  
 LIST OF TABLES  
Table 1: Investigator Global Assessment  (IGA)  Scale  ..................................................46 
Table 2: Rosacea Erythemaa Assessment  Scale .............................................................47 
Table 3: Telangiectasia Assessment  Scale .....................................................................47 
Table 4: Cutaneous Safety  Assessment Scale  ................................................................52 
Table 5: Local  Tolerability  Assessment Scale  ...............................................................53 
Table 6: Process for  Testing  the Secondary  Efficacy  Endpoints ...................................67 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  8 of 85  
 LIST  OF APPENDICES  
Appendix 1: Patient  Instruction Sheet ..................................................................................77 
Appendix 2: PRO – PAPSS  ..................................................................................................79 
Appendix 3: PRO – PAPI  .....................................................................................................80 
Appendix 4: PRO – PGI -S ....................................................................................................81 
Appendix 5: PRO – PGI -C ...................................................................................................82 
Appendix 6: PRO – PGI -TS .................................................................................................83 
Appendix 7: PRO – PGI -SE .................................................................................................84 
Appendix 8: ROSACEA QUALITY OF  LIFE  QUESTIONNAIRE (ROSAQOL)  .............85 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  9 of 85  
 5. PROTOCOL  SYNOPSIS 
5.1. Synopsis 
 
Title:  A Phase 3 Multi- Center, Double -Blind, Randomized, Vehicle-Controlled 
Study of S5G4T-1 in the Treatment of Papulopustular Rosacea  
Study  Number:  SGT -54-01 
Study  Phase:  3 
Indication:  Papulopustular rosacea  
Study  Period:  12 weeks  (84 Days)  
Study  Products:  1. S5G4T-1: Encapsulated  Benzoyl Peroxide (E-BPO)  Cream,  5%, 
developed by Sol -Gel Technologies and manufactured by  
, Montreal, Canada.  
2. S5G4T-2: Vehicle Cream, developed by Sol -Gel Technologies and 
manufactured  by , Montreal, Canada.  
Study  Objectives:  To assess the efficacy and safety of S5G4T -1 compared to S5G4T -1 
Vehicle when  applied  once daily  for 12 weeks  in patients  with 
papulopustular rosacea  
Study  Design:  In this Phase 3, double -blind, vehicle- controlled study, patients will be  
admitted  into this multi- center,  double-blind, randomized, vehicle -
controlled, parallel -group  pivotal study only after a written  informed 
consent has been obtained and after all inclusion/exclusion criteria have 
been met.  Male and female patients at least 18 years of age with 
moderate  or severe  papulopustular rosacea  [Investigator Global  
Assessment (IGA) grade 3 or 4] will be eligible for enrollment for daily  
treatment  with S5G4T-1 or its vehicle  for 12 weeks.  
Study  
Population: Approximately  350 male and female patients,  at least 18 years  of age, who 
meet  the inclusion/exclusion criteria will be enrolled  in the study. 
Investigational 
Sites  It is estimated  that up to 28 study centers  in US will participate  in this 
study. 
Dosing: Patients will be randomized in a 2:1 ratio to the study product or vehicle  
treatment group, respectively. Patients will apply the study product once  
daily for 12 weeks. Patients will use a “pea- size” amount for each area of  
the face (chin, left cheek,  right cheek,  nose, left forehead  and right 
forehead).  The study product will be spread as a thin layer in such a way  
as to provide an even  distribution, avoiding the eyes,  lips, inside the nose, 
mouth and all mucous membranes.  Patients  will receive detailed  
instructions on the method of application and quantity to use in order to  
assure that treatment is harmonized among all patients to best extent possible. 

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  10 of 85  
  
5.1. Synopsis 
 
Methodology: Clinical and  Safety  Evaluations will be performed  at: 
1. Visit 1/Screening  
2. Visit 2/Baseline,  Day  1 
3. Visit 3/Week 2,  Day  15 (± 3  Days)  
4. Visit 4/Week 4,  Day  29 (± 3  Days)  
5. Visit 5/Week 8,  Day  57 (± 3  Days)  
6. Visit 6/Week 12, Day 85 (± 4 Days)/End of Treatment/End of 
Study) 
Patients  will be admitted  into the study after all inclusion/exclusion 
criteria have been met, including a clinical diagnosis of rosacea and after  
written  informed  consent has  been  obtained. Subjects  with  severe rosacea 
who are appropriate for systemic  treatment  need  to be counseled  regarding 
their treatment options by  the Principal  Investigator. 
At each visit, a 5 -point IGA scale of rosacea; rosacea erythema, and  
telangiectasia;  and inflammatory  (papules,  pustules) lesion  counts will be  
performed  and recorded.  
Safety will be assessed at all visits, and will include monitoring of local  
adverse experiences, Investigator Cutaneous Safety Assessment rating of  
dryness and scaling and Local Tolerability Assessment rating of itchi ng 
and burning/stinging on a scale ranging from 0 (None) to 3 (Severe);  
patients will complete a Patient Reported Outcomes (PRO) questionnaire  
at Visit 2,  3, 4, 5 and 6 and Rosacea Quality of  Life Questionnaire  
(RosaQoL) at Baseline and Visit 6  or at early  termination..  
Standardized  photography of facial  rosacea  at Visit  2, 3, 4, 5 and 6 will be 
performed  at select site(s).  
In addition to IGA, at each visit, the following safety measures will be  
recorded:  monitoring for any AE including local  and systemic;  
investigator Cutaneous Safety Assessment rating of erythema, dryness  
and scaling and Local Tolerability Assessments rating of itching and  
burning/stinging on a scale ranging  from 0  (None) to  3 (Severe).  
Urine pregnancy tests will be performed on females of child-bearing 
potential at Screening,  Baseline and every  4 weeks  during study or at early  
termination.  
Regardless of the  duration of the study, patients  that exhibit serious  
adverse event (SAE), will be followed up until the SAE res olves, based  
on investigator’s medical  judgment. 
Clinical Trial Duration Screening:  -35 to 0 days prior to Baseline 
Duration of treatment: 12 weeks/84  days 
Patients  have the right to stop the study for any  reason at any given time.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  11 of 85  
  
5.1. Synopsis 
 
Study product  
dosage and 
Reference  
therapy  Encapsulated Benzoyl Peroxide Cream, 5% or vehicle will be dispensed  
every 4 weeks (Baseline, Week 4 and Week 8) to patients and used daily  
during the study. 
The study product and vehicle will be supplied in 55- gram pumps (total  
weight including pump is 85 grams).  
Patient Inclusion  
Criteria:  Patients  may participate  in the study if they meet  all of the following 
criteria:  
1. Patient  must sign an Institutional Review  Board  (IRB)  approved 
written  informed consent for this study. 
2. Male and female 18 years  of age and older. 
3. Patients must have clinical diagnosis of moderate to severe 
rosacea with a Baseline Investigator’s Global Assessment (IGA)  
Score of 3 (moderate severity)  or 4 (severe) on a  severity  scale  of 
0 to 4. 
4. Have a minimum total of 15 and a maximum total of 70  
inflammatory  lesions (papules and/or pustules) including those 
present  on the nose. 
5. Have two nodules or less (nodule defined as a papule  or pustule 
greater  than 5 mm in diameter)  at Baseline.  
6. Patients must be willing and able to understand and comply with the requirements  of the study, apply the medication  as instructed, 
refrain from use of the following medications (during the study, return for the required treatment period visits, comply with  
therapy  prohibitions, and are able to  complete  the study): 
− topical  rosacea medication  including: Metronizadole 0.75% 
to 1%, Azelaic acid, Brimonidine, Oxymetazoline, Sodium Sulfacetamide 10%, Sulfur 5%, Benzoyl Peroxide, Clindamycin, Erythromycin, Benzoyl Peroxide and Clindamycin, Sulfur lotions,  retinoids, Ivermectin  Cream  1%, 
Ivermectin  lotion 0.5%; or  
− topical  and systemic  (oral  and injectable)  antibiotics  known 
to impact rosacea e.g., tetracycline and its derivatives,  
erythromycin and its derivatives, doxycycline and its derivatives,  minocycline and  its derivatives,  azithromycin  and 
its derivatives, clarithromycin and its derivatives,  
metronidazole and its derivatives, sulfamethoxazole, or 
trimethoprim  and retinoids (e.g.,  isotretinoin)  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  12 of 85  
  
5.1. Synopsis 
 
Patient Inclusion  
Criteria  
(continued):  7. Patients must be willing to minimize or not significantly alter  
controllable external factors that might trigger rosacea flare -ups 
(such as spicy food, thermally hot foods, soups and drinks, hot 
environments, prolonged sun exposure, strong winds, alcoholic beverages,  etc.)  throughout their participation  in the  study. 
8. Patients must be generally healthy and free from any clinically significant disease,  other than rosacea,  that might interfere with 
the study evaluations. 
9. Sexually active females of child -bearing potential, excluding 
women who are sterilized (including Essure procedure, tubal  
ligation,  bilateral oophorectomy or hysterectomy) or 
post- menopausal for at least 2 years, must use one of the following birth control options*: 
− Intrauterine device (IUD) 
− Hormonal (injections,  implants,  transdermal  patch,  vaginal 
ring) 
− Abstinence 
− Oral contraceptives  
− Female condom 
− Diaphragm with spermicides  
− Cervical  cap with spermicides  
− Contraceptive sponge 
* In addition, patients entering the trial that are on hormonal  
contraceptives  must have been  on this method for at least 
3 months (90 days) prior to the trial and continue the method for 
the duration of the trial. Patients  who had used hormonal 
contraception and stopped must have stopped no less than 
3 months prior to Baseline. Patients entering the study who had an Essure  procedure must have had this procedure at least 
3 months  prior to the study and have undergone an Essure  
confirmation test to ensure its efficacy.  A sterile sexual partner  
is not considered an adequate form of  birth  control. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  13 of 85  
  
5.1. Synopsis 
 
Patient Exclusion 
Criteria:  The presence of any of the following will exclude the potential patients  
from  entry  into the study: 
1. Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at baseline or screening visits.  
2. Presence of more than 2 facial  nodules or any nodule greater  than 
1 cm.  
3. Current  or past  ocular rosacea (e.g., conjunctivitis, blepharitis,  or 
keratitis) of sufficient severity to require topical or systemic  
antibiotics.  
4. Presence of any other facial skin condition that might interfere  
with rosacea diagnosis and/or assessment including but not limited to (e.g., on the face: rosacea conglobata, rosacea fulminans, acne vulgaris, acne conglobata, acne fulminans, or secondary acne (chloracne, drug -induced acne, etc.), facial  
pustulosis of the chin, dermatitis (including peri-orbital and seborrheic dermatitis), demodicidosis, facial keratosis pilaris,  
acute lupus erythematous, psoriasis,  eczema,  acneiform  eruptions 
caused by medications, steroid acne, steroid folliculitis, sunburn, rhinophyma, or bacterial  folliculitis).  
5. Any uncontrolled, chronic or serious disease or medical 
condition that  would prevent participation  in a clinical  trial or,  in 
judgment of the Investigator, would put the patient at undue risk 
or might confound the study assessments.  
6. Excessive facial  hair (e.g., beards,  sideburns, moustaches,  etc.) 
that would interfere  with diagnosis or assessment  of rosacea.  
7. History  of unresponsiveness to topical benzoyl peroxide. 
8. Concurrent use of drugs causing acneiform eruptions (e.g., azathioprine, haloperidol, halogens, lithium, systemic corticosteroids, phenytoin, phenobarbital, testosterone, anabolic steroids, isoniazid). 
9. Known  sensitivities  to the  study product ingredients. Allergy  to 
benzoyl peroxide, parabens and glycerin or other ingredients listed  in the investigator brochure. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  14 of 85  
  
5.1. Synopsis 
 
Patient Exclusion 
Criteria  
(continued):  10. Use: 
− within 180 days prior to Baseline or during the study of oral  
retinoids (e.g., Accutane®) or therapeutic vitamin A  
supplements of greater than 10,000 units/day (multivitamins are allowed).  
− within  90 days prior to  Baseline or during the study radiation  
therapy  and/or anti-neoplastic agents.  
− start or change of dose within 90 days prior to Baseline or 
during the study of vasodilators, vasoconstrictors, anticoagulation or beta- blockers therapy  and use throughout 
the study. Use of such therapy must remain constant throughout the study. 
− start or change of dose within 90 days prior to Baseline of 
hormonal treatment  (oral,  implanted,  topical  contraceptives  
and androgens). Use of such therapy must remain constant 
during the study. 
− within 30 days prior to Baseline or during the study of therapeutic Vitamin D supplements of greater than 2,000 
units/day (daily  multivitamins  with  Vitamin  D not exceeding  
more than 2000 IU/day are allowed). If a patient on a 
constant stable prescribed weekly dose, they should remain on this dose during the study. 
− within 30 days prior to Baseline or during the study of (1) systemic steroids, (2) topical retinoids to the face (e.g., tretinoin) (3) systemic (e.g., oral or injectable) antibiotics known to impact rosacea (e.g., tetracycline and its derivatives, erythromycin and its derivatives, doxycycline and its derivatives, minocycline and its derivatives, macrolides and its derivatives, azithromycin and its  
derivatives, clarithromycin and its derivatives, metronidazole and its derivatives, sulfamethoxazole, bactrim or trimethoprim); short term treatment of all other antibiotics  
(not affecting rosacea for) ≤ 14 days for non- rosacea related  
conditions is acceptable, (4) immunosuppressive agents, or immunomodulators (e.g. cyclosporine, tacrolimus, pimecrolimus).  
− of medicated make-up (including anti-aging make-up) throughout the study and significant change in the use  of 
consumer products within 14 days of study entry and 
throughout  the study.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  15 of 85  
  
5.1. Synopsis   
Patient Exclusion  
Criteria  
(continued):  − of niacin  and niacinamide  (Vitamin B3) within  24 hours of  
study entry  and throughout the study. 
− of intranasal and inhaled corticosteroids do not require a 
washout and  may  be used throughout the study if at a  stable  
and standard dose. 
11. Facial  use within 14 days prior to Baseline  or during the study of 
(1) topical steroids, (2) topical anti- inflammatory agents or  
topical non- steroidal anti -inflammatory drugs (NSAID), (3) 
topical antimycotics, (4) any topical rosacea treatments (e.g., Metronizadole 0.75% to 1%, Az elaic acid, Brimonidine,  
Oxymetazoline,  Sodium Sulfacetamide 10%,  Sulfur 5%, Benzoyl 
Peroxide, Clindamycin, Erythromycin, Benzoyl Peroxide and Clindamycin, Sulfur lotions, Retinoids, Ivermectin) or (5) topical antibiotics.  
12. Use on the face within 30 days prior to Baseline or during the study of (1) cryodestruction or chemodestruction, (2) dermabrasion, (3) photodynamic therapy, (4) acne surgery, (5) intralesional steroids, (6) laser  resurfacing  or electrodessication,  
(7) x -ray therapy, (8) pulse dye laser, (9) long-pulsed Nd- YAG 
laser, (10) Intense pulse light or pulse light laser, (11) 
electrocautery  or electrocoagulation, (12) CO
2 laser,  Fractioned  
lasers, or loop electrosurgery, (13) facial peels or other facial 
cosmetic  surgery  (e.g., Thermage®, etc.).  
13. Use of medicated cleansers on the face (e.g., benzoyl peroxide, salicylic acid, sulfur or triclosan) within 7 days of Baseline and throughout the study. 
14. Patient consumes excessive alcohol, abuses drugs, or has a condition that could compromise the patient’s ability to comply  
with study requirements and/or have drug or alcohol addiction requiring treatment in the  past 12 months. 
15. Use of topical astringents or abrasives (e.g., rubs, exfoliating cleansers and products containing salicylic acid and/or alcohol), topical  preparations that contain  spices  or lime,  medicated  topical  
preparations (prescription and OTC products) within 7 days prior to Visit 2 (Baseline)  and throughout the study. 
16. Use of antipruritics (including antihistamines), spa or sauna treatments or chlorine exposure (swimming pool etc.) within 24 hours (1 day) of all study visits (Visit 2, Baseline, through End of Study). 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  16 of 85  
  
5.1. Synopsis 
 
Patient Exclusion 
Criteria  
(continued):  17. Participation in any clinical study involving an investigational product, agent  or device that might influence the intended effects  
or mask the side effects of study product, within 30 days prior to Visit 2 (Baseline)  and throughout the study. 
18. Previous enrollment in  this study  or current enrollment in  this 
study at another participating  site. 
19. Employee (or employee’s  family  member)  of the research  center  
or private practice, or  patients who have a conflict  of interest.  
20. Patients  living  (e.g., siblings, spouses, relatives)  in the same 
household cannot be enrolled in the study at the  same time.  
21. Use of tanning booths, sun lamps or excessive UV radiation  (e.g., 
phototherapy, daily extended exposure or occupational exposure to the sun), sunbathing or excessive exposure to  the sun  1 week  
(7 days) prior to  Baseline and  throughout the study. 
22. Patients  who in the opinion of the investigator, are  unlikely to be 
able to follow the restrictions of the protocol and complete the study. 
Primary Efficacy  
Endpoints:  • Proportion of patients  with the primary  measure of success  “Clear” (0) 
or “Almost clear” (1) in the IGA relative to Baseline  at Week  12 
• Absolute change in inflammatory  lesion  counts from  baseline to 
Week  12 
Secondary  
Efficacy  
Endpoints:  • Percent  change in inflammatory  lesion  count from  baseline to 
Week  12 
• Absolute change in inflammatory  lesion  count from  baseline to 
Week  8 
• Proportion of patients  with the primary  measure of success  “Clear”  
(0) or “Almost clear”  (1) in the IGA relative to Baseline at Week 8  
• Absolute change in inflammatory  lesion  count from  baseline to 
Week  4 
• Proportion of patients  with the primary  measure of success  “Clear”  
(0) or “Almost clear”  (1) in the IGA relative to Baseline at Week  4 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  17 of 85  
  
5.1. Synopsis 
 
Supportive  
efficacy  
endpoints:  • Percent  change in inflammatory  lesion  count at  Week  8 
• Percent  change in  inflammatory  lesion  count at Week 4  
• Mean  change comparison  in PAPSS item 1 (burning) between  
groups from Baseline to  Weeks  4, 8 and 12 
• Mean  change comparison  in PAPSS item  2 (itching) between  
groups from Baseline to  Weeks  4, 8 and 12 
• Mean  change comparison  in PAPSS item 3 (redness)  between  
groups from Baseline to  Weeks  4, 8 and 12 
• Mean  change comparison in PAPSS item 4 (bumps) between  
groups from Baseline to Weeks 4, 8 and 12 Rosacea erythema  
assessment  at Week 12  
• Telangiectasia assessment  at Week 12  
• The proportion of patients in treatment relative to control who  
report  at least “minimally  improved” as measured  by the PGI-C at 
Week  12 
• Mean  change in the components of the PAPI  score between  groups 
from  Baseline to Week  12 
• Proportion of patients  in the treatment  relative  to control achieving 
a three- point improvement in the components of the PAPI score  
from  Baseline to Week  12 
• Patient  Global Impression of Symptom Severity  (PGI -S) at 
Week  12 
• Patient Global Impression of Treatment Satisfaction (PGI -TS) at  
Week  12 
• A set of cumulative distribution function (CDF) curves will be  
generated to allow for the evaluation of within -person change by 
treatment group. Specifically, 5 plots will be generated showing  
the change from baseline to Week 12 [and/or other, earlier time  
points if so desired]  by the cumulative  percent  of subjects  for each 
of the treatment arms (change on the x- axis will be expressed as  
absolute change) on: 
o PAPSS total scale scores;  
o PAPSS item 1 (burning) scores; 
o PAPSS item 2 ( itching) scores;  
o PAPSS item 3 (redness) scores;  and 
o PAPSS  item 4 (bumps) scores  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  18 of 85  
  
5.1. Synopsis 
 
Safety  Endpoints:  • Adverse events  (AEs),  including serious adverse  events  (SAEs)  
occurring at  any time during  the trial.  
• Investigator Cutaneous Safety  Assessment  and Local  Tolerability  
Assessments score at any  time during  the trial.  
Safety:  The incidence of all adverse events reported during the study will be  
summarized by treatment group. Safety will be evaluated by comparing  
the nature, severity and frequency of their adverse event profiles.  Safety  
variables  include Investigator Cutaneous Safet y Assessment  score,  
treatment -emergent adverse events (AEs), SAEs, treatment related AEs,  
AEs leading  to study discontinuation and concomitant medications 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  19 of 85  
  
5.1. Synopsis 
 
Statistical  
Method:  General  Statistical  Methods  
All statistical processing will be performed using SAS® version 9.3 or  
later unless otherwise stated.  Statistical significance will be based on  
two-tailed  tests of the null hypothesis resulting  in p-values  of 0.05 or less. 
Analysis Populations  
The intent -to-treat (ITT)  population will consist of all randomized  patients  
who were  dispensed study product. The safety  population will be 
comprised of all randomized patients who are presumed to have used the  
study product at least once and who provide at least one post- baseline 
safety evaluation.  Patients will be considered per protocol (PP) if they  
complete  the 12- week  evaluation  without noteworthy study protocol 
violations (i.e., any patient  or investigator activity  that could have possibly 
interfered with the therapeutic administration of the treatment or the  
precise evaluation of treatment efficacy).  
Patients  that discontinue from  the study due to an adverse event  related  to 
study treatment  or documented lack of treatment effect  will be included in 
the PP population. Data for these subjects will not be imputed  by multiple  
imputation but rather their data will be imputed with values consistent  
with their status as treatment failures. Prior to breaking the blind, other  
additional criteria  may be added  to the list to accommodate for unforeseen  
events  that occurred  during the conduct of the trial that result  in 
noteworthy study protocol violations 
Evaluations and Analyses 
Inflammatory lesion count will be recorded for each patient at Baseline  
and at Weeks 2, 4, 8 and 12. The absolute and percent change from  
baseline of inflammatory  lesions will be derived  for each patient  at 
Weeks  2, 4, 8 and 12. 
The IGA will be recorded  for each patient  at Baseline,  Weeks  2, 4, 8 and 
12. The IGA will be dichotomized into “success”  and “failure” at 
Weeks  2, 4, 8 and 12 with a patient  considered a success  for those visits  if 
the IGA is at least 2 grades less than baseline and are Clear or Almost  
Clear.  
The Rosacea erythema assessment, and telangiectasia assessment will be  
recor
ded at Baseline, Weeks  2, 4, 8 and 12. 
Patients will be asked to complete a Patient Reported Outcome, PRO  
questionnaire at Baseline, Weeks 2, 4, 8 and 12 and a Rosacea Quality of  
Life, RosaQoL questionnaire at Baseline and Week 12(or at the early  
termination  visit).  
All assessments will  be conducted for both ITT and PP.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  20 of 85  
  
5.1. Synopsis 
 
Statistical  
Method  
(continued):  Statistical  Hypothesis Testing  
Tests  of superiority for the absolute change from  Baseline in inflammatory  
lesions will be based on either parametric or non -parametric methods  
consistent with the statistical assumptions required  to support the 
analyses.  Specifically,  the tests of superiority  will be based  on an 
ANCOVA with factors  of treatment  and analysis  center  and the respective 
Baseline lesion count as a covariate or on ranked data submitted to an  
ANCOVA with factors  of treatment  and analysis  center  and the respective 
Baseline lesion count as a covariate.  If the treatment -by-analysis center  
interaction effect is significant at an alpha less than 0.10, then the effect  
will be included in the model; otherwise it will be  removed. 
A skewness test, based on the methods presented by Zar 1984, will be  
applied  to the residuals resulting  from  an ANCOVA.  A two-sided  p-value  
for the skewness test significant at 0.01 will imply the use of the non- 
parametric method. If a parametric analysis is indicated, the results of the  
parametric analysis will be considered the primary analysis.  Should a  
non-parametric analysis be indicated, the absolute or percent changes in  
inflammatory  lesions will be rank-transformed  prior to submitting  them  to 
the ANCOVA.  Results of the rank- transformed analyses then will be  
considered  the primary  analysis;  however,  results  of the non- rank-
transformed analyses will also be presented.  
The IGA will be dichotomized into “success” and “failure” with a patient  
considered  a success  for those visits  if the Investigator’s Global 
Assessment  is at least 2 grades  less than Baseline  and “Clear”  or “Almost 
Clear”.  The analysis of the dichotomized IGA will be based on a logistic  
regression  test with  factors  of treatment  group and  analysis  center.  
Missing  Efficacy  Data  Imputations  
Missing Week 12 data will be estimated by multiple imputation and  
subsequently analyzed.  Missing lesion count data will be derived for the  
analysis  using the method  of Markov Chain  Monte Carlo  (MCMC)  
multiple  imputation.  The pattern  of missing  observations in each 
treatment  group cannot influence the missing  value estimation  in the other 
because  the imputation  will be conducted independently for each 
treatment  group. 
Safety  
Evaluation: Safety  will be evaluated  by tabulations of adverse  events  (AEs),  
Cutaneous Safety Assessments for dryness and scaling, assessments for  
scores (erythema and telangiectasia) and Patient Global Impression of  
Treatment  Side- Effects  (PGI- SE) will be presented  with descriptive 
statistics at Baseline and at the scheduled study  visits.  Frequencies and  
percentages  for each outcome category  will be included in these statistics.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  21 of 85  
 5.2. Study Flow  Chart  
 
Procedures  Visit  11 Visit  22 Visit 32 Visit 42 Visit 52 Visit  62,3 
(EOT4/ 
EOS5) 
Name of Visit  Screening  
-35 – 0 Baseline  
Day 1  Week  2 
Day 15 Week  4 
Day 29 Week  8 
Day 57 Week  12 
Day 85 
Visit  window    ± 3 days  ± 3 days  ± 3 days  ± 4 days  
Informed  Consent  X      
Demographics  X      
Medical  History/Previous  Therapies  X X     
Brief  Physical  Examination   X    X 
Inclusion/Exclusion  Criteria  X X     
Urine  Pregnancy  Test6 X X  X X X 
IGA X X X X X X 
Inflammatory  Lesion  Counts  X X X X X X 
Assessment  of Eligibility   X     
Rosacea  Erythema  Assessment   X X X X X 
Telangiectasia  Assessment   X X X X X 
Randomization   X     
Cutaneous Safety Assessment and  
Local Tolerability  Assessments   X X X X X 
Administer/  Review  Patient  
Instructions   X X X X  
Weigh Study  Product   X  X X X 
Study  Product  Dispensed   X7  X X  
Provide Cleanser and  
Moisturizer/Sunscreen8  X     
Diary  Card dispensed   X  X X  
Study  Product  Collected     X X X 
Diary  Card collected     X X X 
Patient  Compliance  Reviewed  (Diary)    X X X X 
Concomitant  Therapy  and Medication  
History  Reviewed  X X X X X X 
Adverse  Events  X9 X X X X X 
Photography  (select  site(s))   X X X X X 
Complete  PAPSS, PAPI  and PGI -S10,11  X X X X X 
Complete  PGI-C, PGI-TS and 
PGI-SE12   X X X X 
Complete  RosaQoL13  X    X 
 
 
1 If no washout is needed, Visits 1 and 2 may occur on the same day. If a washout is needed, Visit 2 must occur within one month 35 days of  
Visit  1. 
2 All visit dates  are in reference to Baseline, e.g., Visit  5 occurs  8 weeks  ± 3 days after Baseline  Visit.  
3 All Week 12  procedures  should  be completed  for Patients  who terminate early. 
4 EOT  – end of treatment  
5 EOS  – end of  study  
6 All women  of childbearing  potential  
7 Dispense  one pump  of test material  at the Baseline Visit and dispense  additional  pump at  Visit  4 and 5. 
8 Or study  approved  cleanser  and moisturizer  
9 Adverse  events  after ICF  is signed  will be collected. 
10 PAPSS is Patient Assessment of Papulopustular rosacea Signs and Symptoms; PAPI is Patient Assessment of Papulopustular rosace a Impacts;  
PGI-S is Patient  Global Impression of  Symptom  Severity.  Questionnaires will  be completed prior  to PI assessment.  
11 In case Screening  Visit and Baseline  are on the  same  day, the PRO  questionnaires  should  be completed  prior  to screening  procedures.  
12 PGI-C is Patient Global Impression of Change; PGI-TS is Patient Global Impression of Treatment Satisfaction; PGI -SE is Patient Global  
Impression of  Treatment Side -Effects.  Questionnaires will  be completed prior  to PI assessment.  
13 RosaQoL  is a Rosacea  Quality  of Life questionnaire.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  22 of 85  
 6. LIST OF ABBREVIATIONS  AND  TERMS  
 
AE(s)  Adverse  Event(s)  
ANCOVA  Analysis  of Covariance  
BPO  Benzoyl  Peroxide  
°C Degrees  Centigrade  
CFR  Code  of Federal  Regulations  
CRO  Contract  Research  Organization  
E-BPO  Encapsulated  Benzoyl  Peroxide  
eCRF  Electronic  Case Report  Form  
FDA  Food  and Drug  Administration  
g Grams  
cGCP  current  Good Clinical Practice  
h hour(s)  
IB Investigator’s  Brochure  
ICF Informed  Consent Form  
ICH International Conference on  Harmonisation  
IGA Investigator’s  Global  Assessment  
IND Investigational  New  Drug  
IRB Institutional  Review  Board  
ITT Intent -to-Treat  
IWRS  Interactive  Web  Response System  
MCMC  Markov Chain Monte Carlo  
MedDRA  Medical Dictionary  for Regulatory  Activities  
min Minutes  
mg Milligram 
NRS  Numerical  Rating  Scale  
OTC  Over -the-Counter  
PAPI  Patient  Assessment  of Papulopustular  Rosacea Impacts  
PAPSS  Patient  Assessment  of Papulopustular Rosacea  Signs  and Symptoms  
PGI-C Patient  Global Impression  of Change 
PGI-S Patient  Global  Impression  of Symptom  Severity  
PGI-SE Patient  Global Impression  of Treatment  Side-Effects  
PGI-TS Patient  Global Impression  of Treatment  Satisfaction  
PI Principal  Investigator 
PRO  Patient  Reported  Outcome  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  23 of 85  
  
PP Per Protocol  
SAE  Serious  Adverse  Event  
SOP Standard  Operating  Procedure  
VRS  Verbal  Rating  Scale  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  24 of 85  
 7. INTRODUCTION  AND  BACKGROUND  
S5G4T- 1 is an innovative topical formulation containing 5% encapsulated benzoyl peroxide  (E-
BPO) that Sol -Gel is developing for the treatment of rosacea.  If approved, S5G4T -1 will be  the 
first product containing E -BPO for the treatment of rosacea.  Sol- Gel believes S5G4T -1 has  the 
potential to be as tolerable as,  and more effective than, currently marketed  rosacea dru gs. 
Rosacea is a chronic and recurrent inflammatory dermatological disorder of unknown etiology. 
The disease is common, especially  in fair-skinned people of Celtic  and northern  European  heritage.  
The onset of the disorder is usually between the ages of 30 and 50. Early stages of the disease 
affect  women  more often  than men at a ratio of 3 to 1 ( Jansen and Plewig 1997 and 
McDonnell and Tomecki 2000).  Rosacea usually starts as flushing and subtle redness on the  
cheeks, nose, chin or forehead. Alcohol, hot drinks, spicy foods, stress, sunlight and extreme heat or cold can trigger the onset  of this disease.  If left untreated,  rosacea  can slowly  worsen  over time.  
As the condition progresses, patients experience inflammatory lesions (papules and pustules), 
vivid erythema and telangiectasia.  Patients may develop furuncles, cystic nodules, granulomas  
and tissue hypertrophy, sometimes leading to rhinophyma. 
The first report  on the treatment of rosacea with  benzoyl peroxide as  a single  agent  was described  
by in Montes et al. in 1983. In this limited study, 5% benzoyl peroxide, after 5 to 8 weeks of  
treatment, demonstrated superiority compared to control with respect to papules, pustules and  
erythema but not telangiectasia.  The formulation was a basic f ormulation with benzoyl peroxide  
dissolved and delivered  in acetone.  Irritation  and burning was reported  in both groups, most  likely  
due to the well -known effects of benzoyl peroxide. 
More  recently,  Breneman  et al.  2004 published the results  of a study in collaboration with 
J. Leyden. This study was a double -blind, vehicle -controlled study, using a combination gel  
product of 5% benzoyl peroxide and 1% clindamycin to treat patients having moderate to severe  
rosacea.  The most dramatic effect of the b enzoyl peroxide/clindamycin treatment was on the  
reduction of papules and pustules. Side effects included the well -known effects of benzoyl  
peroxide, burning and itching. 
Yamasaki et al. published a paper in 2007 which may explain why benzoyl peroxide pote ntially  
has a therapeutic benefit in the treatment of rosacea.  The team reported that a protease that splits  
the antimicrobial peptide, cathelicidin, from its protein precursor is elevated in inflammatory  
rosacea.  Cathelicidin subsequently induces the formation of the pro- inflammatory cytokine IL -8. 
It has also been previously reported that Propionibacterium acnes induces elevated levels of  
cathelicidin in the skin.  These observations support the hypothesis that P. acnes has a major role  
in the etiology of rosacea,  and provide a mechanistic  understanding of why benzoyl peroxide may 
have a therapeutic benefit in the treatment of rosacea.  
Rosacea is treated with both systemic and topical therapies.  How
 ever, topical therapies are 
preferable  because of side  effects caused by  the use of systemic therapies.  
According to the U.S. National Rosacea Society, approximately 16 million people in the United  
States  are affected  by rosacea.  According to a study commissioned  by the Sponsor, approximately 
4.8 million people in the United States experience subtype II symptoms and physicians estimate  
that only 20% of the U.S. rosacea population is treated.  The topical drugs approved by the FDA  
to treat subtype II rosacea generated aggregate revenues of approximately $392 million in the  
United  States for the  12 months period ending June 30, 2017. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  25 of 85  
  
 
             
 
      
 
    

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  26 of 85  
 8. OBJECTIVE  
• The primary  objective of this  pivotal study  is: 
1. To assess  the efficacy  and safety  of S5G4T-1 compared  to S5G4T-1 Vehicle when  applied  
once daily  for 12 weeks in patients with papulopustular rosacea.  
The co-primary  efficacy  endpoints are to be evaluated using the following parameters:  
• Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost clear”  
(1) in the IGA relative  to Baseline  at Week  12. 
• Absolute change in inflammatory  lesion counts from baseline to Week  12. 
• The secondary  objective of this pivotal study  is: 
To demonstrate statistical superiority in efficacy  of S5G4T-1 compared  to the vehicle with regard  
to percent change from baseline.  
The co-secondary efficacy  endpoints are: 
• Percent  change in inflammatory  lesion  count from  baseline to Week  12 
• Absolute change in  inflammatory  lesion  count from baseline  to Week 8  
• Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost clear”  
(1) in the IGA relative  to Baseline at  Week  8 
• Absolute change in  inflammatory  lesion  count from baseline to Week  4 
• Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost clear”  
(1) in the IGA relative  to Baseline at  Week  4 
 
• The supportive objective of this  pivotal study  is: 
To determine  t he time required to observe improvement in the efficacy  parameters  associated  with 
clearance  of rosacea for S5G4T -1 compared to vehicle. 
Supportive efficacy  endpoints include the following: 
• Percent  change in inflammatory  lesion  count at  Week  8 
• Percent  change in  inflammatory  lesion  count at Week 4  
• Mean  change comparison  in PAPSS item 1 (burning) between  groups from  Baseline to 
Weeks  4, 8 and 12 
• Mean  change comparison  in PAPSS item 2 (itching)  between  groups from  Baseline to 
Weeks  4, 8 and 12 
• Mean  change comparison in PAPSS item 3 (redness)  between  groups from  Baseline to 
Weeks  4, 8 and 12 
• Mean  change comparison in PAPSS item 4 (bumps) between  groups from  Baseline to 
Weeks  4, 8 and 12 Rosacea erythema assessment  at Week  12 
• Telangiectasia assessment  at Week 12  
• The proportion of patients  in treatment  relative  to control who report  at least “minimally  
improved” as measured by  the PGI -C at Week 12  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  27 of 85  
 • Mean  change in  the components of the PAPI score between  groups from  Baseline to  
Week 12  
• Proportion of patients  in the treatment  relative to control achieving  a three -point 
improvement in the components of the PAPI score from Baseline  to Week  12 
• Patient  Global Impression  of Symptom Severity  (PGI -S) at Week 12  
• Patient  Global Impression  of Treatment  Satisfaction  (PGI -TS) at Week  12. 
• A set of cumulative distribution function (CDF) curves will be generated to allow for the  
evaluation of within- person change by treatment group. Specifically, 5 plots will be  
generated showing the change from baseline to Week 12 [and/or other, earlier time points  
if so desired] by the cumulative percent  of subjects  for each  of the treatment  arms (change  
on the x -axis will be  expressed as  absolute change) on: 
PAPSS total scale scores;  
PAPSS item 1 (burning) scores;  
PAPSS item 2 (itching) scores;  
PAPSS item 3 (redness)  scores;  and 
PAPSS  item 4  (bumps) scores 
 
 
• The safety  objective  of this  pivotal study is: 
The safety objectives of this study are to determine the nature, severity and frequency of the  
adverse event rate, the Cutaneous Safety Assessment and the Local Tolerability Assessment of  
S5G4T-1 compared to the vehicle.  
The safety  endpoints to be assessed include the following: 
• Adverse events (AEs), including serious adverse events (SAEs) occurring at any time  
during the trial.  
• Investigator Cutaneous Safety  Assessment  and Local  Tolerability  Assessments score at any 
time during the trial.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  28 of 85  
 9. ETHICS 
This study will be conducted in compliance with FDA regulations, the ethical principles of the  
Declaration of Helsinki, and the current ICH - Good Clinical Practice (cGCP) guidelines.  The 
investigator and all study staff will conduct the  study in compliance with this protocol. 
The protocol, informed consent documents, any information provided to patients, recruitment  
advertisements and any amendments to these items will have Institutional Review Board (IRB)  
approval prior to their use in the study. Voluntary informed  consent will be given by every  patient  
prior to the initiation of any study related procedures. The rights, safety and well -being of the  
study patients are the most important considerations and prevail over the interests of science and  
society.  
All personnel involved in the conduct of this study must be qualified by education, training and 
experience to perform their assigned responsibilities. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  29 of 85  
 10. INSTITUTIONAL  REVIEW  BOARD (IRB) AND INFORMED  
CONSENT  
Before  study initiation,  this protocol, the investigational brochure for encapsulated  benzoyl 
peroxide cream (E -BPO) in the treatment of rosacea, the informed consent form, and any other  
written  information  given to patients,  and any advertisement  for patient  recruitment  must have IRB 
approval. The investigator will submit documentation of the IRB approval to the Sponsor, Sol-Gel 
Technologies Ltd., or their CRO designee. 
The IRB -approved consent form must include all elements required by FDA, state, and local  
regulations, and may  include appropriate additional element s. 
The investigator/designee will explain the study to each potential patient and the patient must  
indicate voluntary consent by signing and dating the approved informed consent form. The 
consent process will be conducted prior to the start of any study- related procedures including a  
washout period. The investigator must provide the patient with a copy of the consent form, in a  
language the patient  understands. 
The investigator will maintain documentation that informed consent was obtained prior to the  
initiation  of any  study- related procedures.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  30 of 85  
 11. OVERALL STUDY  DESIGN  
This study will be a randomized,  double-blind, multicenter,  parallel  group, active - and vehicle-
controlled pivotal study of the efficacy, and safety of S5G4T -1 and its vehicle for the  treatment 
of papulopustular rosacea for 12 weeks. Approximately 350 patients with moderate to severe 
rosacea (rated 3 or 4 on the 5- point IGA scale) will be enrolled at up to 28 sites. Patients  in this 
randomized, double -blind, vehicle -controlled, p arallel -group multi -center study will be  randomly 
assigned  in a 2:1 ratio to S5G4T-1 or vehicle,  respectively.  Subjects  with severe  rosacea  who are 
appropriate for systemic  treatment  need  to be counseled  regarding  their treatment options by the 
Principal  Investigator. 
Patients will receive once daily treatment with S5G4T -1 or vehicle cream for 12 weeks. After the  
screening period, qualified patients will be randomly assigned at the Baseline visit and treated for 
12 weeks.  Efficacy  assessments  will include facial  inflammatory  lesion  counts and IGA 
assessment ranging from 0 (Clear) to 4 (Severe). Investigators will be provided with instructions  
for lesion counts to ensure consistency of procedure. Patient reported outcomes (PRO) will be  
assessed with the PAPSS (Patient Assessment of Papulopustular rosacea Signs and Symptoms),  
PAPI  (Patient  Assessment  of Papulopustular rosacea  Impacts)  and PGI-S (Patient  Global 
Impression of Symptom Severity) that will be administered at Baseline, Weeks 2,  4, 8 and 12, or  
at early termination.  In addition, the PGI -C (Patient Global Impression of Change), PGI -TS 
(Patient  Global Impression of Treatments  Satisfaction)  and PGI-SE (Patient  Global Impression of 
Treatments Side Effects) will be administered at Weeks 2, 4, 8 and 12, or at early termination  
[FDA Guidance 2009]. Rosacea Quality of Life (RosaQoL) questionnaire will be administered at  
Baseline,  and Week  12, or at early  termination.  Safety  will be assessed  at all visits  and will include  
monitoring local  and systemic  adverse events  (AEs);  the investigator Cutaneous Safety  
Assessment rating of erythema, dryness and scaling and Local Tolerability Assessments rating of  
itching  and burning/stinging on a scale ranging from 0 (None) to 3 (Severe ). 
Patients  will return  to centers  for IGA,  lesion  counts, PRO  questionnaire, , Investigator Cutaneous 
Safety Assessment and Local Tolerability Assessments at Weeks 2, 4, 8 and 12. At Week 12 (or  
at the early termination visit) patients will be asked to complete RosaQoL questionnaire. Adverse  
events and concomitant medications will be assessed throughout the treatment period. A urine  
pregnancy test is required  at Visit 1,  2, 4, 5 and 6 for  all females of  child -bearing  potential.  
Clinical Evaluations will be performed  at: 
• Visit 1/Screening  
• Visit 2/Baseline,  D ay 1 
• Visit 3/Week 2,  Day  15 (± 3  Days)  
• Visit 4/Week 4,  Day  29 (± 3  Days)  
• Visit 5/Week 8,  Day  57 (± 3  Days)  
• Visit 6/Week  12, Day 85 (± 4 Days)/End of Treatment)  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  31 of 85  
 12. STUDY  POPULATION  
12.1. Randomization and Blinding 
It is planned that approximately 350 patients who meet the inclusion/exclusion criteria will be  
enrolled in this study at up to 28 U.S. study sites. Patients will be at least 18 years of age and  
older, of either gender. Efforts will be made to enroll patients ages matching the target study  
population. 
The study product will be administered  in a double-blinded fashion, i.e., the treatment  assignment 
will not be known to the patient, to study personnel, or Sol -Gel and its representatives.  Patients  
will be instructed not to discuss the study product with the study personnel. Patients will be  
randomly assigned in a 2:1 ratio as follows: 
• E-BPO  Cream,  5% (S5G4T-1) (234 patients)  
• Vehicle Cream (S5G4T -2) (117 patients)  
Each patient who signs an informed consent, meets inclusion/exclusion criteria, and successfully 
completes the screening procedures, will be enrolled in the study. The patient randomization  
schedule will be a permuted block design stratified by investigational site. Blocks will be  
composed of 3 treatment assignments in a ratio of 2:1 study product and vehicle, respectively.  
Complete  blocks from  the randomization schedule  will be allocated  to investigational sites as they 
randomize patients  to maintain  the randomization ratio of 2:1 study product and vehicle,  
respectively.  
Additionally, the staff involved in data management  and statistical evaluation  will remain  blinded 
until identification of  the per  protocol population is finished  and a database lock memo is  issued. 
The randomization schedule and treatment  code will  not be revealed  to the patients,  study 
personnel, Sol -Gel or its representatives until after the database lock, except to the Medical  
Monitor or Principal Investigator for an emergency. Access to the randomization list will be  
maintained by and limited to the unblinded Biostatistician and the designated personnel directly responsible for labeling of study materials. The Medical Monitor will not have access to the  
randomization list, but may determine that unblinding one or all patients may be necessary in the  
case that the safety of study patients is at risk. In an emergency, the study blind may be broken 
only if: 
• In the opinion of the Medical Monitor and/or the PI, it is in the patient's best interest to do  
so 
• Knowledge of the treatment will alter  the clinical  management  of the patient 
In the case of an emergency that requires unblinding, the Investigator can request to unblind the  
patient  without prior contact  with the Medical  Monitor although follow -up between  the 
Investigator and Medical Monitor must occur so that all parties are aware of the unblinding. Although it is recommended  that the Investigator contact  the Medical  Monitor prior to unblinding 
any patient, in instances where this is not feasible or advisable the PI may directly access the  
patient's treatment assignment.  In all situations, the Interactive Web Response System (IWRS)  
will be used to obtain treatment  assignment information  with limited  access  to only the above-
designated  individuals, and any  unblinding will be  documented as  a protocol deviation. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  32 of 85  
 12.2. Inclusion Criteria  
To be included in the study, patients  must meet the  following eligibility  /inclusion  criteria:  
1. Patient must sign an Institutional Review Board (IRB) approved written informed consent for  
this study. 
2. Male and female 18 years  of age and older. 
3. Patients  must  have clinical  diagnosis of moderate to severe rosacea  with a Baseline (IGA  Score  
of 3 (moderate severity)  or 4 (severe) on  a severity  scale of  0 to 4. 
4. Have a minimum total of 15 and a maximum total of 70 inflammatory  lesions (papules and/or 
pustules) including those present on the nose. 
5. Have two nodules or less (nodule defined  as a papule or pustule greater  than 5 mm in diameter)  
at Baseline.  
6. Patients  must be willing  and able to understand and comply with the requirements  of the study, 
apply the medication as instructed, refrain from use of the following medications (during the  
study, return  for the required  treatment  period visits,  comply with therapy  prohibitions, and are 
able to complete the  study): 
• topical  rosacea  medication  including: Metronizadole 0.75% to 1%, Azelaic acid,  
Brimonidine, Oxymetazoline, Sodium Sulfacetamide 10%, Sulfur 5%, Benzoyl Peroxide,  
Clindamycin, Erythromycin, Benzoyl Peroxide and Clindamycin, Sulfur lotions, retinoids, 
Ivermectin  Cream 1%,  Ivermectin lotion 0.5%, or 
• topical  and systemic  (oral  and injectable)  antibiotics  known to impact  rosacea e.g., 
tetracycline and its derivatives, erythromycin and its derivatives, doxycycline and its  
derivatives,  minocycline  and its derivatives, azithromycin  and its derivatives,  
clarithromycin  and its derivatives,  metronidazole and  its derivatives,  sulfamethoxazole, or 
trimethoprim and retinoids (e.g., isotretinoin) 
7. Patients  must be w illing  to minimize  or not significantly  alter controllable external  factors  that 
might trigger rosacea flare-ups (such  as spicy  food, thermally  hot foods, soups and  drinks, hot 
environments, prolonged sun exposure, strong winds, alcoholic beverages, etc.) throughout  
their participation  in the study. 
8. Patients must be generally healthy and free from any clinically significant disease, other than  
rosacea, that might interfere  with the  study evaluations. 
9. Sexually active females  of child -bearing potential, excluding women  who are sterilized  
(including Essure  procedure, tubal ligation,  bilateral  oophorectomy or hysterectomy) or 
post- menopausal for at least  2 years, must use one of the following birth control options*: 
• Intrauterine device (IUD)  
• Hormonal (injections,  implants,  transdermal  patch,  vaginal ring) 
• Abstinence 
• Oral contraceptives,  
• Female condom 
• Diaphragm with spermicides  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  33 of 85  
 • Cervical  cap with spermicides  
• Contraceptive sponge 
* In addition, patients  entering  the trial that are on hormonal contraceptives  must have been  on 
this method for at least 3 months (90 days) prior to the trial and continue the method for the  
duration of the trial. Patients who had used hormonal contraception and stopped must have  
stopped no less than 3 months prior to Baseline. Patients entering the study who had an  
Essure  procedure must have  had this procedure at  least  3 months prior to the study and have 
undergone an Essure confirmation test to ensure its efficacy. A sterile sexual partner is not  
considered  an adequate form of  birth control. 
12.3. Exclusion Criteria  
Patients are excluded  from  the study if any  of the following c riteria  are met:  
1. Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their  
study participation  or were found to have positive pregnancy test at baseline or screening  visits.  
2. Presence  of more  than  2 facial  nodules or any  nodule greater than 1 cm.  
3. Current or past ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient 
severity  to require topical or systemic antibiotics.  
4. Presence of any other facial skin condition that might interfere with rosacea diagnosis and/or  
assessment  including but not limited  to (e.g., on the face:  rosacea  conglobata, rosacea 
fulminans, acne vulgaris, acne conglobata, acne fulminans, or secondary acne (chloracne, 
drug- induced acne, etc.), facial pustulosis of the chin, dermatitis (including peri -orbital and  
seborrheic dermatitis),  demodicidosis, facial  keratosis  pilaris,  acute  lupus erythematous,  
psoriasis,  eczema,  acneiform  eruptions caused  by medications,  steroid  acne,  steroid  folliculitis,  
sunburn, rhinophyma, or bacterial  folliculitis).  
5. Any uncontrolled, chronic or serious disease or medical  condition that would prevent  
participation  in a clinical  trial or, in judgment of the Investigator, would put the patient  at undue 
risk or might confound the study assessments.  
6. Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would interfere with  
diagnosis or assessment  of rosacea.  
7. History  of unresponsiveness to topical benzoyl peroxide. 
8. Concurrent use of drugs caus ing acneifo rm eruptions (e.g., azathioprine, haloperidol, halogens, 
lithium, systemic corticosteroids, phenytoin, phenobarbital, testosterone, anabolic steroids,  
isoniazid). 
9. Known sensitivities to the study product ingredients. Allergy to benzoyl peroxide, parabens 
and glycerin or other ingredients listed in the  investigator brochure. 
10. Use: 
• within 180 days prior to Baseline or during the study of oral retinoids (e.g., Accutane®) or 
therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are  
allowed).  
• within  90 days prior to Baseline radiation  therapy  and/or anti -neoplastic agents.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  34 of 85  
 • start or change of dose within  90 days prior to Baseline  or during the study of vasodilators, 
vasoconstrictors, anticoagulation or beta -blockers therapy and use throughout the study. 
Use of such therapy must remain constant throughout the study. 
• start or change of dose within 90 days prior to Baseline of hormonal treatment (oral,  
implanted, topical contraceptives an d androgens). Use of such therapy must remain  
constant during the study. 
• within  30 days prior to Baseline or during the study of therapeutic Vitamin  D supplements 
of greater than 2,000 units/day (daily multivitamins with Vitamin D not exceeding more  
than 2000 IU/day are allowed). If a patient on a constant stable prescribed weekly dose,  
they should remain on this dose during the study. 
• within 30 days prior to Baseline or during the study of (1) systemic steroids, (2) topical  
retinoids to the face (e.g., tretinoin)  (3) systemic  (e.g., oral or injectable)  antibiotics  known 
to impact rosacea (e.g., tetracycline and its derivatives, erythromycin and its derivatives, 
doxycycline and its derivatives,  minocycline and its derivatives,  macrolides  and its 
derivatives,  azithromycin and its derivatives,  clarithromycin  and its derivatives,  
metronidazole and its derivatives, sulfamethoxazole, bactrim or trimethoprim); short term  
treatment of all other antibiotics (not affecting rosacea  for) ≤ 14 days for non- rosacea  
related conditions is acceptable, (4) immunosuppressive agents, or immunomodulators  
(e.g. cyclosporine, tacrolimus, pimecrolimus). 
• of medicated  make-up (including anti-aging make-up) throughout the study and significant 
change in the use of consumer products within 14 days of study entry and throughout the  
study. 
• of niacin  and niacinamide  (Vitamin  B3) within  24 hours of study entry  and throughout the 
study. 
• of intranasal and inhaled corticosteroids do not require a washout and may be used throughout the study if at a stable  and standard dose. 
11. Facial  use within  14 days prior to Baseline  or during the study of (1) topical  steroids, (2) topical  
anti-inflammatory  agents  or topical  non-steroidal anti-inflammatory  drugs (NSAID),  (3) 
topical antimycotics, (4) any topical rosacea treatments (e.g., Metronizadole 0.75% to 1%,  
Azelaic acid , Brimonidine, Oxymetazoline, Sodium Sulfacetamide 10%, Sulfur 5%, Benzoyl  
Peroxide, Clindamycin, Erythromycin, Benzoyl Peroxide and Clindamycin, Sulfur lotions,  
Retinoids, Ivermectin) or  (5) topical antibiotics.  
12. Use on the face within 30 days prior to Baseline or during the study of (1) cryodestruction or  
chemodestruction, (2) dermabrasion, (3) photodynamic therapy, (4) acne surgery,  (5) 
intralesional steroids, (6) laser resurfacing or electrodessication, (7) x- ray therapy, (8) pulse  
dye laser, (9) long- pulsed Nd- YAG laser, (10) Intense pulse light or pulse light laser, (11)  
electrocautery  or electrocoagulation, (12) CO
2 laser,  Fractioned  lasers,  or loop electrosurgery,  
(13) facial  pe els or other facial cosmetic surgery  (e.g., Thermage®,  etc.).  
13. Use o f medicated cleansers on the face (e.g., benzoyl peroxide, salicylic acid, sulfur or  
triclosan)  within 7 days of Baseline and throughout the study. 
14. Patient consumes excessive alcohol, abuses drugs, or has a condition that could compromise  
the patient’s ability to comply with study requirements and/or have drug or alcohol addiction  
requiring treatment in the  past 12 months. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  35 of 85  
 15. Use of topical  astringents or abrasives  (e.g., rubs, exfoliating  cleansers  and products containing 
salicylic acid and/or alcohol), topical preparations that contain spices or lime, medicated 
topical preparations (prescription and OTC products) within 7 days prior to Visit 2 (Baseline)  
and throughout the study. 
16. Use of antipruritics (including antihistamines), spa or sauna treatments or chlorine exposure  
(swimming  pool etc.) within  24 hours (1 day) of all study visits  (Visit 2, Baseline,  through End 
of Study). 
17. Participation in any clinical study involving an investigational product, agent or device that  
might influence the intended effects or mask the side effects of study product, within 30 days  
prior to Visit 2 (Baseline) and throughout the study. 
18. Previous enrollment in this study or current enrollment in this study at another participating  
site. 
19. Employee  (or employee’s  family  member)  of the research  center  or private practice,  or patients  
who have a conflict of interest.  
20. Patients living (e.g., siblings, spouses, relatives) in the same household cannot be enrolled in  
the study at the  same time.  
21. Use of tanning  booths, sun lamps  or excessive UV radiation  (e.g., phototherapy, daily  extended  
exposure or occupational  exposure to the sun), sunbathing or excessive exposure to the sun 
1 week (7  days) prior to  Baseline and throughout the study. 
22. Patients  who in the opinion of the investigator, are unlikely to be able to follow the restrictions  
of the protocol and complete the  study. 
12.4. Prohibited, Previous and Concomitant Therapies  
Any previous rosacea therapies must be stopped for the appropriate washout period as specified  
below and as noted in the exclusion criteria:  
• Topical astringents or abrasives or preparations that contain spices or lime, medicated  
topical preparations applied  to the face (prescription  and OTC  products) within  7 days prior  
to Baseline.  
• Use of medicated cleansers on the face (e.g., benzoyl peroxide, salicylic acid, sulfur or  
triclosan)  within 7 days of Baseline.  
• Topical  anti-rosacea  treatments – 2 weeks  prior to Baseline.  
• Topical  antibiotics,  antimicrobials – 2 weeks  prior to  Baseline.  
• Topical  ant i-inflammatories  on the face such as corticosteroids, vasoconstrictors and 
non-steroidal  anti-inflammatory  drugs (NSAID) – 2 weeks prior to  Baseline.  
• Topical  retinoids – 30 days prior to Baseline.  
• Systemic  rosacea treatments,  corticosteroids, antibiotics  – 4 weeks  prior to Baseline.  
• Systemic  retinoids – 6 months prior to Baseline.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  36 of 85  
 Other than the study products, no other topical medications are permitted to be used on the face . 
All topical  or systemic  medications  listed  above and under exclusion  criteria  are prohibited. Other  
prohibited treatments  include but are not limited  to astringents, toners, clarifying  lotions, 
medicated  shaving products, cosmetic  procedures and chemical  peeling  products used on the face.  
A stable  regimen  of inhaled  corticosteroids  for stable  medical  conditions (in the 2 months  
preceding enrollment) and antibiotic treatment of an infection of less than 14 days are allowed  
during the study. 
No medicated cleansers or moisturizers are allowed on the face.  Only the sponsor -provided 
cleanser and moisturizer/sunscreen (or a study -approved cleanser or moisturizer/sunscreen) will  
be allowed to be used on the face during the study. Study product shall be applied to clean skin  
and no cleanser should be applied to the face within two hours of study product application.  
Approved moisturizer/sunscreen may be applied after 30 minutes or more of study product  
application. Patients who use make- up must have used the same brands/types of make -up for a  
minimum period of 1 month (30 days) prior to study entry and must agree to not change make-up 
brand/type or frequency of use throughout the study. Patients should not apply the moisturizer or  
sunscreen  or combinatio n of them  or wear  make-up during study visits  as it may interfere  with the 
evaluator’s assessments.  
All concomitant therapies used during the study must be recorded on the Concomitant Therapy electronic case  report form (eCRF).  
Therapies (medication and non- medication therapies) not restricted by the protocol may be used  
during the study for the treatment or prevention of disease or to maintain good health.  Vitamins  
and mineral  supplements are permitted  at dosages considered  by the investigator as reasonable for 
maintaining good health. Non-prohibited chronic therapies being used at Baseline (Visit 2) may  
be continued. Patients may use systemic anti- inflammatory agents [i.e., NSAIDs (ibuprofen or  
aspirin) for pain relief] as needed (with no more than 7 days of consecutive use) throughout the  
study. Prophylactic use of low dose aspirin (81 mg) is allowed. Patients may use acetaminophen  
for pain relief, as needed  throughout the study. 
Any changes in concomitant therapies during the study must be recorded on the Concomitant  
Therapy  form  at each visit.  The reason  for any change in concomitant  therapies  should be reported  
as, or in conjunction with, an adverse event except  as noted below: 
• Prophylactic therapies, such as vaccines, must be recorded on the Concomitant Therapy  
form,  but the reasons  for these  therapies should not be reported as adverse events. 
• Changes in therapy for pre -existing conditions that are not related to a worsening of the  
condition must be reported on the Concomitant Therapy form, but the reasons for these  
changes should not be reported as adverse events. The condition must be reported in the  
Medical  History. 
If a patient receives prohibited treatment during the study, the patient may be allowed to continue in the study at the  discretion  of the investigator and Sponsor / Medical Monitor. 
Patients should avoid UV exposure by sun bathing or tanning parlors.  
12.5. Precau
 tions  
The following precautions  are to be taken during this study: 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  37 of 85  
 1. Patients  should avoid contact  of the study product with the eyes,  mouth, and lips or on any cuts 
or broken skin. In case of accidental  exposure, the eyes should be rinsed  with plenty of water.  
2. The study product should not be applied to cuts, abrasions, eczematous  or sunburned skin. 
3. Patients  should wash hands before  and after applying study product. 
4. Patients should allow the treated area to completely dry for at least 30 minutes after applying 
the study product to avoid spreading it on other areas of the face (e.g., eyes, ears, neck, etc.)  
and pillow cases.  
5. The study product should be spread evenly in a thin layer on each area of the face (chin, left  
cheek,  right cheek,  nose, left forehead  and right forehead);  excessive rubbing must be avoided. 
6. The study product should not be applied  more than once daily  and patients  should not use more  
than the recommended amount. 
7. Patients  should not wash their  face more  than 2 or 3 times  a day. 
8. Facial  makeup  (non- medicated)  may be applied  according to the patient’s  normal  daily  routine 
(but not prior to 30 minutes after study product application).  
9. Patients should not apply moisturizers, make -up, creams, lotions, powders or any topical  
product they do not routinely use on their face 
10. Patients  should not cover  the treated  area with a bandage (occlusive dressing) or other types of 
dressing after applying the study product. 
11. Patients should limit sun exposure, including sunlamps (non- prescription UV light sources);  
avoid tanning beds/booths/parlors and sauna while  using the study product. 
12. Patient should use moisturizer with SPF supplied by the Sponsor or from study- approved list  
product and protective apparel (e.g. wide - brimmed hat) when outdoors.  Patients should wait  
approximate ly 30 minutes  after study product is applied  on the face before  applying a 
sunscreen.  Weather extremes, such as wind or cold, may be irritating to patients receiving  
treatment.  
13. UVA/UVB  tre atments  are also prohibited. 
14. Patients  must not wear make-up to any  study visits, so as not to interfere with the  evaluations. 
If a patient  comes  to his/her visits  with  make-up on his/her face,  the patient  will be allowed  to 
wash his/her face with a non- medicated cleanser and must wait at least 30 minutes before any  
study evaluation is made by  the Principal  Investigator (PI) or Sub-Investigator (Sub- I). 
15. Patients  should consult the investigator with any questions regarding concomitant medications.  
16. Abrasive cleansers  or washes,  alcoholic toners, astringents are prohibited throughout the study. 
17. “Waxing”  as a depilatory method should be avoided on skin treated  with  study product. 
18. Patients should be informed that local skin reactions [dryness, burning/stinging, pruritus  
(itching), scaling/peeling] may  occur.  
19. Patients should minimize or not significantly alter consumption of any foods and beverages  
that might provoke erythema,  flushing, and blushing (including spicy  food, alcoholic 
beverages,  and thermally  hot drinks, including hot coffee and tea)  throughout the study. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  38 of 85  
 13. STUDY  PROCEDURES  
13.1. Study Patient  Identification  
When the patient signs the informed consent, he/she will be assigned a three (3) -digit patient 
number. The complete patient ID will consist of the 3 -digit site number followe d by the 3-digit 
patient  number: e.g.,  (first  patient  screened  at site ). This number will remain  with the 
patient  for the duration of the study and will not be reassigned  to another patient  should the patient  
screen  fail. 
13.2. Screen  Failure  and Discontinuation Criteria  
A screen failure is a patient who is not randomized/enrolled in the study due to ineligibility, after  
signing an Informed Consent Form, and would not have received study product. The Informed  
Consent Form signed by the patient should be kept with the source document for patients who do  
not pass the  screening procedures. The documentation should include identification of the  
eligibility criterion or criteria that were and were not met.  The patient should not be re -screened  
for this s tudy without Sol- Gel’s approval.  
Although encouraged to complete the study whenever possible, patients are free to discontinue  
their participation in this study at any time and for any reason without prejudice. A patient may  
be withdrawn from the study prior to study completion for any of the following  reasons:  
• Investigator opinion that  it is not in  the patient’s  best interest  to continue. 
• Patient  Request  /Withdraw  Consent – Whenever  the patient  decides  it is in his/her best 
interest  to withdraw. 
• Lack  of Efficacy/ Worsening  of Condition. 
• Adverse Event – when  the investigator thinks it’s  in the patient’s  best interest 
• Lost to Follow -up – Documentation confirmed at minimum by two phone calls and  
certified  letter.  Every  effort  should be made to capture an explanation  for the lost- to follow- 
up event.  
• Protocol Violation  – When  requirements  of the protocol are not respected,  especially  when  
patient safety  is concerned. 
• Pregnancy. 
• Unblinding of study product. 
Study staff should make efforts to encourage patients to complete the study on time. If a patient  
prematurely withdraws during the study, every effort should be made to complete at least the  
Week 12/End of Study assessments.  
In the case of patients who discontinue due to an Adverse Event, the Inv estigator will conduct  
follow- up contacts with the patient until the Investigator, Sponsor and Medical Monitor agree the  
event is satisfactorily  resolved and/or stabilized. 
Patients  discontinued early from the  study shall not be replaced. 

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  39 of 85  
 13.3. Patient  Screening  and Enrollment 
The study personnel will review the IRB approved informed consent form with each patient and  
give the patient an opportunity to have all questions answered before proceeding. The consent  
form must be signed by each patient before the patient is enrolled into the study. A copy of the  
signed consent will be given to every  patient  (or legally  authorized  representative)  and the original 
will be maintained with the patients’ records. 
Patients that require a  wash -out of more than 30 days from their initial informed consent/assent  
signing must be re -consented before any  further study procedures can begin.  
13.4. Assignment of Randomization 
The patient randomization schedule will be a permuted block design stratified by investigational  
site. Blocks will be composed of 3 treatment assignments in a ratio of 2:1 study product and 
vehicle, respectively.  Complete blocks from the randomization schedule will be allocated to  
investigational sites as they randomize p atients.  Patients will be randomized through the IWRS  
and assigned a unique randomization ID indicating treatment group.  The study product supplies  
will be packed in 4 pumps per kit and will be numbered in a scrambled randomized method. The 
kits will be di spensed  by the IWRS  according to the randomized  treatment  group. 
The first supplied pump in each kit is marked  A (e.g. number of pump within  a kit is XXXXA),  at 
Visit 4/ Week 4 the patient will return the pump and will be dispensed with the next pump which  
is marked B.  At Visit 5/ Week 8, the patient will return the pump and will be dispensed with a  
pump marked C.  Pump marked as D may be dispensed to patients who lost/damaged/ran- out of  
study product. 13.5. Demographics/Medical   History  
A demographic profile and complete medical history will be recorded prior to starting study  
product. The medical history will include a complete review of all current diseases and their  
respective  treatments.  
13.6. Concomitant   Medications  
Concomitant medications and any medications taken in the 30 days prior to signing informed 
consent will be recorded as prior/concomitant medications (using their generic name, if known)  
with the corresponding indication. The medications to be recorded will include prescription and  
over-the- counter (OTC) medications and dietary supplements. All medications taken on either a  
regular or “prn” basis, including vitamins, aspirin and acetaminophen, should be recorded on this  
page prior to commencing  the use of the study product. 
13.7. Physical  Examination  
The investigator, sub- investigator or appropriately delegated and qualified designee will perform  
a brief physical examination, prior to the patient starting study product. The exam will include  
heart, lung, abdomen evaluation as well as recording height, weight and vital signs. Vital signs  
are to include sitting  blood pressure, oral temperature, heart rate  and respiratory  rate. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  40 of 85  
 13.8. Urine  Pregnancy  Test 
Females  of childbearing potential (excluding women  who are surgically  sterilized  or post-
menopausal for at least 2 years), in addition to having a negative urine pregnancy test, must  be 
willing  to use an acceptable form  of birth  control during the study. An investigator could repeat  the 
pregnancy test at any time during the study if there is any suspicion or possibility that the  patient 
is pregnant. Urine pregnancy test will also be conducted starting at Visit 1/Screening and  at each 
visit [Baseline, Weeks 2, 4, 8 and 12 (End of Study)]. For the purpose of this study, the  
following are considered acceptable methods of birth  control: intrauterine  device (IUD);  
hormonal (injections, implants, transdermal patch, vaginal ring); abstinence; oral contraceptives;  
female  condom; diaphragm with spermicides;  cervical  cap with spermicides; contraceptive 
sponge. 
Patients entering the trial that are on hormonal contraceptives must have been on this method for  
at least 3 months (90 days) prior to the trial and continue the method for the duration of the trial.  
Patients who had used hormonal contraception and stopped must have stopped no less than 3  
months prior to Baseline. Patients entering the study who had an Essure procedure must have had 
this procedure at least 3 months prior to the study and have undergone an Essure  confir mation  test 
to ensure its efficacy.  A sterile  sexual  partner is not considered  an adequate form  of birth  control. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  41 of 85  
 13.9. Study Flow  Chart  
 
Procedures  Visit  11 Visit  22 Visit 32 Visit 42 Visit 52 Visit  62,3 
(EOT4/ 
EOS5) 
Name of Visit  Screening  
-35 – 0 Baseline  
Day 1  Week  2 
Day 15 Week  4 
Day 29 Week  8 
Day 57 Week  12 
Day 85 
Visit  window    ± 3 days  ± 3 days  ± 3 days  ± 4 days  
Informed  Consent  X      
Demographics  X      
Medical  History/Previous  Therapies  X X     
Brief  Physical  Examination   X    X 
Inclusion/Exclusion  Criteria  X X     
Urine  Pregnancy  Test6 X X  X X X 
IGA X X X X X X 
Inflammatory  Lesion  Counts  X X X X X X 
Assessment  of Eligibility   X     
Rosacea  Erythema  Assessment   X X X X X 
Telangiectasia  Assessment   X X X X X 
Randomization   X     
Cutaneous Safety Assessment and  
Local Tolerability  Assessments   X X X X X 
Administer/  Review  Patient  
Instructions   X X X X  
Weigh Study  Product   X  X X X 
Study  Product  Dispensed   X7  X X  
Provide Cleanser and  
Moisturizer/Sunscreen8  X     
Diary  Card dispensed   X  X X  
Study  Product  Collected     X X X 
Diary  Card collected     X X X 
Patient  Compliance  Reviewed  (Diary)    X X X X 
Concomitant  Therapy  and Medication  
History  Reviewed  X X X X X X 
Adverse  Events  X9 X X X X X 
Photography  (select  site(s))   X X X X X 
Complete  PAPSS, PAPI  and PGI -S10,11  X X X X X 
Complete  PGI-C, PGI-TS and 
PGI-SE12   X X X X 
Complete  RosaQoL13  X    X 
 
 
1 If no washout  is needed, Visits  1 and 2 may  occur  on the same  day. If a washout  is needed, Visit 2  must occur  within  35 days of Visit  1. 
2 All visit dates  are in reference to Baseline, e.g., Visit  5 occurs  8 weeks  ± 3 days after Baseline  Visit.  
3 All Week 12  procedures  should  be completed  for Patients  who terminate  early. 
4 EOT  – end of treatment  
5 EOS  – end of  study  
6 All women  of childbearing  potential  
7 Dispense  one pump  of test material  at the Baseline Visit  and dispense  additional  pump at Visit 4 and  5. 
8  Or study  approved  cleanser  and moisturizer  
9 Adverse  events  after ICF  is signed  will be collected. 
10 PAPSS is Patient Assessment of Papulopustular rosacea Signs and Symptoms; PAPI is Patient Assessment of Papulopustular rosace a Impacts;  
PGI-S is Patient  Global Impression of  Symptom  Severity. Questionnaires will  be completed prior  to PI assessment.  
11 In case Screening Visit and Baseline  are at the same  day, the PRO  questionnaires  should  be completed prior  to screening  procedures.  
12 PGI-C is Patient Global Impression of Change; PGI -TS is Patient Global Impression of Treatment Satisfaction; PGI -SE is Patient Global  
Impression of  Treatment Side -Effects.  Questionnaires will  be completed prior  to PI assessment.  
13 RosaQo L is a Rosacea Quality  of Life  questionnai re 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  42 of 85  
 13.10. Screening  Visit (Visit 1) 
If no washout is needed, Visits 1 (Screening) and 2 (Baseline) may occur on the same day. If a 
washout is needed, Visit  2 (Baseline) must occur within 35 days of Visit 1 (Screening). The 
following procedures will be conducted at this visit: 
• Obtain  a signed and dated,  written  informed  consent  for all patients  prior to any study 
related  procedures. 
• Confirm  the patient  meets  the inclusion/exclusion criteria  as outlined in Section  12.2 and 
Section  12.3. 
• Record  any adverse events.  
• Perform  a urine  pregnancy test for all females  of childbearing potential (see Section 12.2);  
the results must be negative for the patient  to be enrolled. 
• Report the medical history  and demographics for the patient.  
• Record  the patient’s  concomitant  medications  and/or therapies  on Concomitant Therapy  
form  as outlined in Section 13.8. 
• Perform  investigator’s global assessment  (IGA)  to determine  eligibility  (See Section  14.1) 
• Perform  facial  inflammatory  lesion  counts to determine  eligibility: ( Section  14.2).  
• Determine  if patient requires  washout and  schedule Baseline Visit.  
13.11. Baseline Visit (Visit 2, Day 1) 
The following procedures will be conducted at this visit: 
• Confirm  the patient continues to  meet  the inclusion/exclusion criteria.  
• Update since Screening  Visit the medical  history for the patient.  
• Ask the patient to complete  PAPSS,  PAPI  questionnaire (see Appendix 2 and A ppendix 3 ). 
Patient will also complete the PGI -S questionnaire (see Appendix 4).  The PAPSS, PAPI  
and PGI-S questionnaires are to be completed  prior to any other assessments  or procedures 
as des cribed in Section 14.5. In case Screening Visit and Baseline are at the same day, the  
PRO  questionnaires should be completed prior to screening  procedures. 
• Ask the patient  to complete  Rosacea  Quality  of Life (RosaQoL) questionnaire (see 
Appendix 8).  
• Perform  brief physical examination  as described  in Section  13.7. 
• Perform  a urine pregnancy test for all females  of childbearing potential (see Section 13.8);  
the results must be negative for the patient  to be enrolled. 
• Update since screening the patient’s concomitant therapies on Concomitant Therapy form  
as outlined in Section 13.6. 
• Perform  the efficacy  evaluations including the Investigator’s Global  Assessment,  
inflammatory lesion counts, rosacea erythema assessment, and telangiectasia assessment  
described  in Sections  14.1 to 14.4. Every  effort  shall  be made to have the same  investigator  
perform  the Baseline and  Visit 6/Week 12  evaluations for the same patient.  
• Perform Cutaneous Safety Assessment and Local Tolerability Assessment as described in  
Sections  16.1 to  16.2. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  43 of 85  
 • Take standardized  photography of face (at selected  sites,  see separate photographic manual  
for instructions) as described in Section 15. 
• Weigh  the study product before  dispensing. 
• Instruct the patient on the study product application as described in Appendix 1. Pump 
usage will be demonstrated by the site personnel on a sample pump at the clinic to help 
assure  the patient  understands the procedure. 
• Dispense the Patient Instruction Sheet and Diary Card to the patient (see Appendix 1 for 
appropriate instructions for study patients).  
• Record  any adverse events.  
• Instruct the patient that throughout the study overexposure of the face to sunlight should  
be avoided. Instruct  the patient  to use the sponsor-provided cleanser  and 
moisturizer/sunscreen; any  exposure to tanning beds must be avoided during the study. 
• Perform randomization for study product by using IWRS.  
• Dispense study product pump to patient. 
• Remind  patient to  not wear make -up to  all subsequent visits  
• Schedule the next study visit.  
13.12. On treatment (Visit 3) – Week 2, Day 15 (± 3 days)  
The following procedures will be conducted at this visit: 
• Ask the patient  to complete  PAPSS,  PAPI  questionnaire (see Appendix 2 and Appendix 3 ). 
Patient  will also complete  the PGI-S questionnaire (see Appendix 4),  PGI-C (see 
Appendix 5),  PGI-TS (see Appendix 6) and PGI-SE (see Appendix 7).  The PAPSS,  PAPI,  
PGI-S, PGI -C PGI -TS and PGI -SE questionnaires are to be completed prior to any other  
assessments or procedures as described in Section  14.5. 
• Observ e and query the patient in a non- directive fashion about any adverse events since  
the previous study visit.  Initiate  or update the appropriate adverse event form  as required.  
• Query  the p atient  about any changes  in concomitant therapies  since the previous study visit 
and update the Concomitant Therapy eCRF  as required.  
• Perform  the efficacy  evaluations including the Investigator’s Global  Assessment,  
inflammatory lesion counts, rosacea erythema assessment, and telangiectasia assessment  
described  in Sections  14.1 to 14.4. 
• Perform Cutaneous Safety Assessment and Local Tolerability Assessment as described in  
Sections  16.1 to  16.2. 
• Take standardized  photography of face (at selected  sites,  see separate  photographic manual  
for instructions) as described in  Section 15. 
• Review  the patient’s  compliance with the study requirements (review  patient diary).  
• Record  number of missed  doses on the appropriate eCRF  page.  
• Review  the study product application instructions with the patient.  
• Schedule/confirm the next study visit.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  44 of 85  
 13.13. On-treatment Visits (Visits 4 and 5) – Weeks 4 and 8, Days 29 and 57 (± 3 days)  
The following procedures will be conducted at these visits:  
• Ask the patient  to complete  PAPSS,  PAPI  questionnaire (see Appendix 2 and Appendix 3 ). 
Patient  will also complete  the PGI-S questionnaire (see Appendix 4),  PGI-C (see 
Appendix 5),  PGI-TS (see Appendix 6) and PGI-SE (see Appendix 7).  The PAPSS,  PAPI,  
PGI-S, PGI -C PGI -TS and PGI -SE questionnaires are to be completed prior to any other  
assessments or procedures as described in  Section 14.5. 
• Observe and query the patient in a non-directive fashion about any adverse events since  
the previous study visit.  Initiate  or update the appropriate adverse event form as required.  
• Query  the patient  about any changes  in concomitant  therapies  since the previous study visit 
and update the Concomitant Therapy eCRF  as required.  
• Perform  a urine  pregnancy test for all females  of childbearing potential (see Section  12.2).  
• Perform  efficacy  evaluations:  IGA,  inflammatory  lesion  counts, rosacea  erythema 
assessment,  and telangiectasia assessment  described  in Sections  14.1 to  14.4. 
• Perform Cutaneous Safety Assessment and Local Tolerability Assessment as described in  
Sections 16.1 to 16.2. Take standardized photography of face (at selected sites, see 
separate photographic manual for instructions) as described in Section  15. 
• Review the patient’s compliance with the study requirements; collect and review the  
Patient  Diary  Card.  
• Dispense a Diary  Card to  the patient  
• Record  number of missed doses on the appropriate eCRF  page.  
• Review  the study product application instructions with the  p atient.  
• Collect  and weigh  returned study product pump. 
• Weigh and dispense the next pump of study product. 
• Schedule/confirm the next study visit.  
13.14. On-treatment (Visit 6) – Week 12, Day 85 (± 4 days) or End of Treatment or Early  
Termination  
The following procedures will be conducted at this visit: 
• Ask the patient to complete  PAPSS,  PAPI  questionnaire (see Appendix 2 and Appendix 3 ). 
Patient  will also complete  the PGI-S questionnaire (see Appendix 4),  PGI-C (see 
Appendix 5),  PGI-TS (see Appendix 6) and PGI-SE (see Appendix 7).  The PAPSS,  PAPI,  
PGI-S, PGI -C PGI-TS and PGI -SE questionnaires are to be completed prior to any other  
assessments or procedures as described in Section 14.5. 
• Ask the patient  to complete  Rosacea  Quality  of Life (RosaQoL) questionnaire (see 
Appendix 8).  
• Observe and query the patient in a non- directive fashion about any adverse events since  
the previous study visit.  
• Query  the patient  about any changes  in concomitant therapies  since the previous study visit 
and update the Concomitant Therapy eCRF.  
• Perform  physical  examination  as described  in Section  13.7. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  45 of 85  
 • Perform  efficacy  evaluations:  IGA,  inflammatory  lesion  counts, rosacea  erythema 
assessment,  and telangiectasia assessment  described  in Sections 14.1 to 14.4. The 
evaluator  who performed  the Baseline evaluations should perform  all subsequent 
evaluations for a patient.  when this is not possible, it is recommended that another  
delegated  evaluator  with overlapping experience with the patient  may perform  the 
evaluations. 
• Perform Cutaneous Safety Assessment and Local Tolerability Assessment as described in  
Sections  16.1 to  16.2. 
• Take standardized  photography of face (at selected  sites,  see separate photographic manual  
for instructions) as described in Section 15. 
• Review the patient’s compliance with the study requirements; collect and review the  
Patient  Diary  Card.  
• Record number of missed doses and report the last date the patient applied the study  
product. 
• Perform  a urine  pregnancy test for all  females  of childbearing potential (see Section  12.2).  
• Collect  and weigh the study product. 
• Complete  the End  of Study/Study Termination  eCRF.  
• Discharge the patient from the study. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  46 of 85  
 14. CLINICAL  OUTCOME  ASSESSMENTS 
The determination  of efficacy  will be based  on investigator  evaluations of the signs and symptoms 
of rosacea.  Evaluators must be a physician or have appropriate documented experience and  
training. Every effort will be made to ensure appropriate training is provided to the investigators  
for consistent diagnosis and evaluation of rosacea. 
For consistency  of evaluations,  the same designated  evaluator  who performs  the Baseline  
assessments shall perform the assessments at Visit 6/Week 12; when this becomes impossible,  
another delegated  evaluator may  perform the assessments.  
14.1. Investigator Global Assessment  (IGA)  
The Investigator Global Assessment  (IGA)  will be performed  at Screening/Baseline,  Weeks  2, 4, 
8 and 12 (End of Study) visits.  
Patients  are eligible  for enrollment if they have facial  rosacea with a global severity  of a 3 
(moderate)  or a 4 (severe) on the IGA  scale.  
The IGA scale provided in Table 1 will be used to describe the severity  grade and subsequent 
score:  
 
Table 1: Investigator Global Assessment  (IGA) Scale 
 
Grade  Description  
0 – Clear  Skin clear  of inflammatory  papules  or pustules  
1 – Almost Clear  Very  few small  papules  or pustules  and very mild dull erythema  is present  
2 – Mild  Few small  papules  or pustules  and mild dull or light pink erythema  is present  
3 – Moderate  Several  to many  small  or larger  papules  or pustules  and moderate light to bright  red 
erythema  is present  
4 – Severe Numerous  small  and/or  larger  papules  or pustules  and severe  erythema  that is bright  red to 
deep red  is present  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  47 of 85  
 14.2. Inflammatory  Lesion  Counts 
Inflammatory lesions (papules and pustules) counts will be performed at Screening, Baseline,  
Weeks 2, 4, 8 and 12 (End of Study) visits. At Screening/Baseline patients must have at least 15  
and not more than 70 inflammatory  lesions (papules, pustules) on the face.  
Papules  and pustules are defined  as follows: 
• Papule  – A solid, elevated inflammatory  lesion  equal  to or less than  5 mm in diameter  
• Pustule  – An elevated  inflammatory  lesion  equal  to or less than 5 mm in diameter,  contains 
pus (yellow- white exudate)  
Nodules will not be  included in the inflammatory  lesion count and are defined as: 
• Nodule/Cyst – Palpable solid inflammatory lesion, greater than 5 mm in diameter, has  
depth, not necessarily  elevated  
14.3. Erythema  Severity  Assessments 
Erythema is defined  as redness  of the skin. It will be scored  on a scale of 0 (none) to  3 (severe)  at 
Baseline,  Weeks  2, 4, 8, and 12 (End  of Study) visits.  The Rosacea Erythema Assessment  Scale  is 
provided in Table 2. 
 
 
Table 2: Rosacea  Erythemaa Assessment  Scale 
 
Grade  Description  
0 – None  No visible  erythema  
1 – Mild  Slight erythema (dull  or light pink),  centro -facial  
2 – Moderate  Definite  erythema (light to bright  red), either  centro -facial  or generalized  to whole  face 
3 – Severe Severe erythema  (bright  red to deep  red), either  centro -facial  or generalized  to whole  face 
a Generalized  erythema  associated  with rosacea  
 
 
14.4. Telangiectasia Assessment  
Facial  telangiectasia will be evaluated  on a scale of 0 to 3 at Baseline and Weeks  2, 4, 8 and 12 
(End  of Study) visits; the  Telangiectasia is provided in Table 3  
 
Table 3: Telangiectasia  Assessment  Scale 
 
Grade  Description  
0 – None  No Telangiectasia 
1 – Mild  Only  a few fine vessels discernible,  involves  approximately  10% or less of facial  area 
2 – Moderate  Multiple and more prominent fine vessels, involves approximately 10 – 30% of the facial  
area 
3 – Severe Numerous  and prominent  fine and/or  courser  vessels,  involves  more  than 30% of the facial  
area 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  48 of 85  
  
 
 
 
 
14.5. Patient  Reported  Outcomes  (PRO) 
There are six PRO questionnaires to be administered in the study and each is summarized below.  
Each will be administered to all patients during the designated study visits with instruction from  
the Study Staff  that they  be completed:  
• Only by the patient without amendment or interpretation of the patient’s response by a  
clinician  or anyone else. 
• Prior to any other assessments or procedures.  
In the event the patient skips any quest ionnaire items; the Study Staff will ask the patient to  
complete the form.  The PRO questionnaire data will be entered into EDC, and a copy will be  
placed  with the  patient  source at  the site  according to the ICH-GCP  guideline (4.9.5). 
The PAPSS ( Appendix 2 ): The PAPSS is a 4 -item questionnaire that asks patients to assess the  
severity  of their  rosacea symptoms (burning, itching, redness,  and bumps) in the 24 hours prior to  
assessment on an 11- point numeric rating scale (NRS) ranging from “0=none” to “10=worst  
possible symptom”. The questionnaire can be completed  in less than one minute  and is 
administered via pen -and-paper at the Baseline visit and site visits at Weeks 2, 4, 8 and 12 (End  
of Study) or early  termination.  Items  can be scored  individually as well  as together to form  a total 
score.  In the present  context, within  visit scores  from  Items  1 (burning), 2 (itching), and 4 (bumps)  
are summed  and averaged to  create a total score  that will be used to evaluate efficacy  hypotheses. 
The PAPI ( Appendix 3):  The PAPI is a 3 -item questionnaire that asks patients to assess the  
papulopustular rosacea related embarrassment, self -consciousness, and frustration in the 7 days  
prior t o assessment on an 11 -point NRS ranging from 0 [“not (concept) at all”] to 10 [“extremely 
(concept)”].  The questionnaire can be completed in less than one minute and is administered via  
pen-and-paper at the Baseline visit and site visits at Weeks 2, 4, 8 and 12 (End of Study) or early 
termination.  Items  can be  scored individually as well as  together to form a total score.  
PGI-S (Appendix 4):  The PGI -S is a single item questionnaire that asks respondents to describe  
the severi ty of their rosacea symptoms “right now” (i.e., at the present moment) on a five -point 
verbal response scale ranging from “Clear” (face is clear, no redness) to “Severe” (face has  
numerous small and/or large bumps, severe redness). Patients are encouraged to look in a mirror  
to help with their response and the questionnaire can be completed in less than 30 seconds. The 
PGI-S is administered via pen -and-paper at the Baseline visit and site visits at Weeks 2, 4, 8 and  
12 (End of Study) or early termination. Though data generated from the PGI -C can be supportive  
of efficacy hypotheses, the primary purpose of the tool is to support anchor -based analyses that  
will inform how researchers may interpret the meaning of change in the primary and secondar y 
assessments.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  49 of 85  
 PGI-C (Appendix 5 ): The PGI -C is a single item questionnaire that asks respondents to describe  
the change they  have noticed in their rosacea symptoms since the start  of the study a 7-point VRS  
ranging from “Very much improved” to “Very much worse”. Patients are encouraged to look in a 
mirror to help with their response and  the questionnaire can be completed  in less than 30 seconds. 
The PGI -C is administered via pen -and-paper at the site visits at Weeks 2, 4, 8 and 12 (End of  
Study) or early termination. Though data generated from the PGI -C can be supportive of efficacy  
hypotheses, its primary  purpose is to support anchor- based  analyses  that will inform  how 
researchers may  interpret  the me aning of change in the primary  and secondary assessments.  
PGI-TS (Appendix 6):  The PGI-TS is a single item questionnaire that asks respondents to describe 
how satisfied  they  are “right now” with  the rosacea  treatment  administered  as part of the study on 
a 5-point VRS ranging from “I am very satisfied” to “I am very dissatisfied”. The questionnaire  
can be completed in less than 30 seconds and is administered via pen- and-paper at the site visits  
at Weeks 2, 4, 8 and 12 (End of Study) or early termination. Though data generated from the  
PGI-TS can be used for other purposes, its primary purpose is to support anchor -based analyses  
that will inform  how researchers  may interpret  the meaning  of change in the primary  and secondary 
assessments.  
PGI-SE (Appendix 7):  The PGI-SE is a single item questionnaire that asks respondents to describe  
how bothered they are “right now” with the rosacea  treatment  administered  as part of the study on 
a 5-point VRS  ranging from  “I am not bothered” to “I am extremely  bothered”. The questionnaire  
can be completed in less than 30 seconds and is administered via pen- and-paper at the site visits  
at Weeks 2, 4, 8 and 12 (End of Study) or early termination.  Though data generated from the  
PGI-TSE can be used for other purposes, its primary purpose is to support anchor -based analyses  
that will inform  how researchers  may interpret  the meaning  of change in the primary  and secondary 
assessments.  
14.6. Ros acea Quality  of Life (RosaQoL) 
There is a symptom subscale with seven  questions (items  2, 6, 9, 16, 17, 18 and 19 in Appendix 
8) , a functional subscale with 3 questions (items  13, 15 and 21 in Appendix 8) and an emotion  
subscale with 11 questions (items 1, 3, 4, 5, 7, 8, 10, 11 12, 14 and 20 in Appendix 8) to be  
administered in the study. The questionnaire will be administered to all patients during the  
designated study visits with the appropriate instructions from the Study Staff. The questionnaire  
should be completed:  
• Only by the patient without amendment or interpretation of the patient’s response by a  
clinician  or anyone else. 
• After  completion  of the Patient  Reported  Outcomes  (PRO) questionnaires 
In the event the patient skips any questionnaire items; the  Study Staff will ask the patient to  
complete  the form.  The QoL questionnaire data will be entered  into the EDC  system  by the Study 
Staff, and a copy will be placed with the patient source documents at the site according to the  
ICH-GCP  guideline (4.9.5). 
All items should be scored  for the following answers:  
• Never:  1 
• Rarely:  2 
• Sometimes: 3 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  50 of 85  
 • Often:  4 
• All the  time: 5  
 
The Site Staff and anyone else provided with a copy of the RosaQoL instrument for the purpose  
of the study will be instructed that the RosaQoL instrument is protected by Common Law  
copyright. No part of this may be reproduced or transmitted in any form or by any means, now  
known or to be invented or adapted, for purpose of financial  gain or profit.  
An overall total score will be calculated; this score will be the unweighted mean of all RosaQoL  
questions. In addition to the total score, each subscale (symptom, functional and emotion) will  
also have a score calculated;  these scores  will the unw eighted  mean  of the group of questions that  
comprise the subscale.  Further details  on the handling of missing  responses and  calculation  of the 
subscale scores will be  detailed  in the Statistical Analysis Plan  (SAP).  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  51 of 85  
 15. PHOTOGRAPHY  
Standardized photography of facial rosacea at Baseline, and at the site visits at Weeks 2, 4, 8 and 
12 (End  of Study) will be performed  at select  sites.  These photographs will be optional for patients  
at the selected  sites and will not be used for efficacy  assessment  purposes. Participating  
investigators shall refer to  separate photographic manual for instructions. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  52 of 85  
 16. SAFETY  EVALUATIONS  
Safety  will be assessed  by monitoring incidence of Cutaneous Safety  Assessment,  Local  
Tolerability  Assessment  and adverse  events  reporting; at Baseline,  at all treatment  and end-of-
treatment  visits.  
16.1. Cutaneous Safety  Assessments 
The evaluator will assess local application site cutaneous reactions by rating the dryness and  
scaling at the Baseline visit and site visits at Weeks 2, 4, 8 and 12 (End of Study) or unscheduled 
visits. The evaluator will determine the score for each of these variables by direct evaluation. The 
definitions of grades provided in Table 4 will be applied to these evaluations. The Cutaneous  
Safety  Assessment  of dryness and scaling will be  made by the investigator at the  time of  the visit.  
 
Table 4: Cutaneous  Safety  Assessment  Scale  
 
Grade  Description  
Dryness  
0 – None  No dryness  
1 – Mild  Slight but definite  dryness  
2 – Moderate  Moderate dryness  
3 – Severe Marked  dryness  and/or  cracking  
Scaling  
0 – None  No scaling  
1 – Mild  Barely  perceptible  scaling  
2 – Moderate  Obvious  but not profuse  scaling  
3 – Severe Heavy  scale production  and/or  peeling  
 
 
Application  site reactions  (dryness and scaling)  are not to be recorded  as adverse events  unless 
they result  in either: 
• The temporary  discontinuation of the study product. 
• The discontinuation of the  patient from the study. 
• The use of a new concomitant medication  in order to  treat this  event.  
Any other application  site reaction  not listed  above (such  as pain)  should be recorded  as adverse  
events  in the source document and eCRFs.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  53 of 85  
 16.2. Local  Tolerability  Assessments 
The evaluator  will assess  local  application  site tolerability  by rating  the itching  and 
burning/stinging at the Baseline visit and site visits at Weeks 2, 4, 8 and 12 (End of Study) or  
unscheduled visits. The evaluator will determine the score for each of these variables by asking 
the patient to grade their experience over the past 24 hours . The definitions of grades provided  
in Table  5 will be applied to these evaluations.  The Local  Tolerability  Assessment  evaluations  of 
itching  and burning/stinging will be  made by the investigator at the  time of the visit.  
 
Table 5: Local Tolerability  Assessment  Scale  
 
Grade  Description  
Itching  
0 – None  No itching  
1 – Mild  Slight itching,  not really  bothersome  
2 – Moderate  Definite  itching  that is somewhat  bothersome  
3 – Severe Intense  itching  that may interrupt  daily  activities  and/or  sleep  
Burning/Stinging  
0 – None  No burning/stinging  
1 – Mild  Slight burning/stinging sensation;  not really  bothersome  
2 – Moderate  Definite  warm,  burning/stinging sensation  that is somewhat  bothersome  
3 – Severe Hot burning sensation that causes definite discomfort and may interrupt daily activities or  
sleep  
 
 
Application  site reactions  (itching  and burning/stinging) are not to be recorded  as adverse events  
unless they result in either: 
• The temporary  discontinuation of the study product. 
• The discontinuation of the patient  from the  study. 
• The use of a new concomitant medication  in order to  treat this event.  
Any other application  site reaction  not listed  above should be recorded  as adverse events  in the 
source document and eCRFs. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  54 of 85  
 17. ADVERSE  EVENTS  
17.1. Departure  from  the Protocol for  Individual Patients  
When  an emergency  occurs requiring a departure from  the protocol for a patient,  departure will be 
only for that patient. In such circumstances, the investigator or other physician in attendance will  
contact  the Medical  Monitor or the Sponsor by telephone and follow up with a written  description 
as soon as possible.  The overseeing IRB should also be notified. 
17.2. Definitions  
An adverse event (AE) is defined as any untoward medical occurrence in a patient administered a 
medicinal product and which does not necessarily have to have a causal relationship with this  
treatment.  An adverse event can therefore be any unfavorable and unintended sign, symptom, or  
disease temporally associated with the use of a medicinal product, whether or not considered  
related  to this medicinal product. 
A serious adverse event  (SAE) is an  adverse event that  results in any of the following outcomes: 
• Death  
• Life-threatening event  (i.e., the patient  was, in the opinion of the investigator, at immediate  
risk of death  from  the event  as it occurred.  It does not include an event  that, had it occurred  
in a more severe form, might have caused death) 
• Requires  in-patient hospitalization  or prolongs hospitalization  
• A persistent or significant disability/incapacity or substantial disruption of the ability to  
conduct normal life  functions 
• Congenital anomaly/birth  defect  
• Other adverse events that may be considered serious based upon appropriate medical  
judgment, may jeopardize the patient  and may require medical or surgical intervention to 
prevent one of the outcomes listed above. 
Immediately Reportable Adverse Events (IRAE) is any serious AE or any AE that necessitates  
discontinuation of study product, including pregnancy. 
Unexpected Adverse Event is any adverse drug experience, the specificity or severity of which is  
not consistent with the current approved product labeling (package insert) for the study product, 
the Investigator’s Brochure,  or as  described  in the clinical  protocol and consent materials.  
Intensity  of Adverse  Events  are the maximum intensity  of an AE during a day  should be recorded  
on the eCRF.  If the intensity  of an AE changes  over a number of days, then separate entries  should 
be made having distinct onset dates for the changes in severity.  
• Mild - A Es are usually transient, requiring no special treatment, and do not interfere with  
patient’s  daily  activities.  
• Moderate - AEs typically introduce a low level of inconvenience or concern to the patient  
and may interfere wit h daily activities, but are usually ameliorated by simple therapeutic  
measures.  
• Severe - AEs interrupt a patient’s usual daily activity and traditionally require systemic  
drug therapy  or other treatment.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  55 of 85  
 17.3. Causal  Relationship  to Study product 
The following criteria  should be used in assessing  the apparent  causal  relationship  of an AE to 
study product: 
Definitely  - The  AE: 
• follows a reasonable temporal  sequence from  study product administration 
• abates  upon discontinuation of the study product (de- challenge)  
• is confirmed by reappearance of the reaction on repeat exposure 
Probably - The  AE: 
• follows a reasonable temporal  sequence from  study product administration 
• abates  upon discontinuation of the study product (de- challenge).  
• cannot be re asonably explained by the known characteristics of the patient’s state.  
Possible - The  AE: 
• follows a reasonable temporal  sequence from  study product administration 
• but that  could readily  be produced by a number of other factors.  
Unlikely  - The  AE: 
• follows a reasonable temporal  sequence from  study product administration. 
• could have been  produced by either  the patient’s  clinical state  or by study product 
administration.  
Not related  - The  AE: 
• does not have a reasonable temporal association  with the  administration  of study product 
• has some other obvious explanation for the event.  
17.4. Eliciting  and Reporting of Adverse Events 
The investigator will periodically  assess patients  for the occurrence of adverse events.  In order  to 
avoid bias in eliciting  adverse events,  the patient  or parent/legally  authorized  representative should 
be asked  a non-specific question (e.g., “How  have  you been  feeling  since your last visit?”)  to assess  
whether any AE has been experienced since the last visit.  All adverse events (as defined in  
Section 17.2), either observed by the Investigator or one of his/her medical collaborators, or  
repor
ted by the patient spontaneously, or in response to direct questioning, will be reported and 
documented in the source and the study reporting forms. When reporting an adverse event, the  
Investigator must assign a severity grade to each event and declare an opinion on the relatedness  
of the event to the study product or procedure.  Serious or unexpected adverse events must be  
reported to the CRO within 24 hours of when the Investigator first learns of the occurrence of the  
event.  
Adverse events will be documented in the source document and recorded in a timely manner on  
case report forms.  Adverse event s that are identified at the last assessment visit (or the Early  
Termination  Visit) must be  recorded on the AE eCRF  with the  status of the  AE noted. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  56 of 85  
 Adverse event  reporting begins from  the signing of informed  consent/assent. Study product-
related adverse events should be followed until resolved or 30 days after the final study  
treatment. Regardless the duration of the study, patients that exhibit serious adverse event (SAE),  
will be followed up until the SAE resolves, based on inves tigator’s medical judgment or are  
considered to be chronic (stabilized for at least 30 days). All events that are ongoing at this time  
will be recorded as ongoing on the eCRF.  
17.5. Expedited Reporting Responsibilities  of the Study Center  
For any serious or unexpected adverse event, the Sponsor or its designee must be notified within  
24 hours of when the Investigator first learns of the occurrence of the event. Expedited reporting  
requirements for serious adverse events are described below.  Adequate information must be  
collected  with  supporting documentation to complete a standard report  for submission to  Sol- Gel. 
The adverse event term on the AE eCRF and the SAE report should agree exactly. Special  
attention  should be given to recording hospitalizations and concomitant medications.  
Patients with unresolved study or product -related adverse event(s) or serious adverse event(s)  
should be followed by the investigator until the events are resolved, events determined to be  
chronic or the patien t is lost to follow-up. Resolution means  the patient  has returned  to the Baseline  
state of health, or the investigator does not expect any further improvement or worsening of the  
adverse event.  The investigator should continue to report any significant fol low-up information  
to the sponsor up to the point that the event has resolved. Any serious adverse event reported by  
the patient to the investigator that occurs within 30 days after the last assessment, and are  
determined  by the investigator to be reasonably  associated  with the use of the study product, should 
be reported to the sponsor within 24 hours of when the Investigator first learns of the occurrence  
of the event.  
When reporting a serious adverse event (SAE) the Investigator (or the Study Coordinator) will  
promptly report  any serious adverse event  or pregnancy  to the Sponsor or its designee by telephone 
email, immediately after the investigator becomes aware of the event.  An SAE form should be  
completed and sent by fax, email, or overnight courier to the Sponsor or its designee within 24  
hours of knowledge of the event by the site. In many cases, only pre liminary information will be  
available.  Appropriate follow up information should be sought (hospital discharge summaries, 
operative reports etc.) and a follow up SAE report form submitted. A designation of causality 
from the study product should always be included with a follow up report. Assess and report the  
causality  of the event.  
17.6. Submitting  an Expedited Safety  Report to the IRB 
Once all supporting documentation is received for the reported event, the Medical Monitor, in  
conjunction with Sol-Gel, will determine  if the safety  report  is eligible  for expedited  review.  When  
expedited safety reporting to regulatory authorities is indeed required, the Investigator should 
review and update any newly available materials at once.  Follow- up queries may be sent to the  
study center to further clarify  the event.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  57 of 85  
 The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected related  
AEs to regulatory authorities on an expedited basis, according to the ICH E2A Guideline and to 
other regulatory authorities according to national and local regulations as required. The Sponsor, 
or its designee, is responsible for prompt submission to the IRB or EC of any expedited SAE  
reports submitted to regulatory authorities. All investigato rs participating in ongoing clinical  
studies will receive copies of the SAE reports submitted on an expedited basis to regulatory authorities  
17.7. SAE  & AEs Requiring Discontinuation of Study Drug, including Pregnancies  
ANY SAE,  WHICH  OCCURS  AFTER  A PATIENT  HAS  ENTERED  THE STUDY,  WHETHER  
OR NOT RELATED TO STUDY PRODUCT, MUST BE REPORTED TO THE SPONSOR OR  
ITS DESIGNEE  IMMEDIATELY  (WITHIN  24 HOURS)  VIA TELEPHONE,  EMAIL  OR 
FACSIMILE.  IF INITIALLY  REPORTED  VIA TELEPHONE,  THIS  MUST  BE FOLLOWED -
UP BY A FACSIMILE OR EMAIL OF THE WRITTEN SAE REPORT WITHIN  24 HOURS 
OF THE CALL  TO THE SPONSOR OR  ITS DESIGNEE.  
Non-serious events  that require discontinuation of study product (including laboratory 
abnormalities)  should be reported  to the Sponsor or its designee immediately  and within  1 working 
day. 
Patients who discontinue due to experiencing study product -related adverse events should be  
followed clinically until their health has returned to baseline status, or until all parameters have  
returned to normal.  It is expected that the investigator will provide or arrange appropriate  
supportive care for the patient.  
A patient who experiences a severe adverse event related to study product will be discontinued  
from the study, but, regardless of the duration of the study, patients that exhibit serious adverse  
event  (SAE),  will be followed up until the SAE  resolves,  based  on investigator’s medical  judgment 
or are considered to be chronic (stabilized for at least 30 days). For safety reporting instructions 
see SAE  and Pregnancy  Form Report Instructions. 
17.8. Pregnancy  
At the time, Principal Investigator or site personnel becomes aware that a study patient became  
pregnant following study participation, the Principal Investigator or designee will report the  
pregnancy immediately by phone and/or by faxing a completed Pregnancy Report to the Sponsor  
or its designee within one working day of being notified of the pregnancy  report. 
The report  will include  the following elements:  
• Patient  (mother’s) coded study identifier;  
• Date of patient’s  last menstrual  period; 
• Total  accumulated  dose of study treatment administered  to date;  
• Date of  study product administration.  
The investigator will follow the patient until completion of the pregnancy and must assess the  
outcome in the shortest possible time but not more than 30 days within completion of the  
pregnancy. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  58 of 85  
 Upon delivery, miscarriage or abortion, the Principal Investigator or designee must forward a  
follow-up Pregnancy Report with any relevant  information  on the present  condition of the fetus  to 
the Sponsor or its designee, including: 
• Mother’s  coded  study identifier(s);  
• Gestational  age at  delivery, miscarriage or abortion; 
• Birth  weight, gender, length  and head  circumference,  if available;  
• Apgar scores  recorded  after  birth, if available;  
• Any abnormalities.  
If the outcome of the pregnancy meets the criteria for immediate classification of an SAE (e.g.,  
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to be  
documented], stillbirth, neonatal death, or congenital anomaly), the investigator will report the  
event by phone and by faxing a completed SAE report form to the Sponsor  or its designee within  
one working day of being notified of the pregnancy  report.  
If the trial is completed  before  the outcome of the pregnancy is known, the Sponsor or its designee 
will assume  the responsibility  for following up on the pregnancy. The Sponsor or its designee  will 
contact the Investigator or Study coordinator on or around the potential expected date of delivery  
to follow -up on the outcome of pregnancy and will also check on the status of the infant 8 weeks  
post- delivery.  Upon awareness  of the pregnancy outcome and known status  of the infant following 
8 weeks of delivery, the investigator will complete the applicable pregnancy report forms and fax 
to the Sponsor or its designee within 1 day of being notified. 
17.9. Post Study Adverse Events 
17.9.1. Non-serious  Adverse Events  
Adverse events  that are identified  at the last assessment  visit (or the Early  Termination  Visit)  must 
be recorded on the AE eCRF  with the  status of the AE  noted. 
17.9.2. Serious  Adverse Events  
Serious adverse events that are identified on the last assessment visit (or the Early Termination  
Visit)  must be recorded  on the AE eCRF  page and reported  to Sol- Gel according  to the procedures  
outlined above. Patients with unresolved previously reported serious adverse events, or any new  
serious adverse  events  identified  on the last assessment  visit,  should be followed by the 
investigator until the events are resolved, or the patient is lost to follow -up. Resolution means the  
patient has returned to the baseline state of health, or the investigator does not expect any further  
improvement or worsening of the adverse event. The investigator should continue to report any  
significant follow -up information to Sol -Gel up to the point that the event has resolved. Any 
serious adve rse event  reported  by the patient  to the investigator that occurs  after the last 
assessment,  and are determined  by the investigator to  be reasonably  associated  with  the use of the 
study product, should be reported to Sol- Gel. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  59 of 85  
 18. STUDY  PRODUCTS / CLINICAL  SUPPLIES  
18.1. Method of Treatment  Assignment 
Patients who satisfy all the inclusion and none of the exclusion criteria will be randomized to one  
of two treatment arms.  Randomization will be performed  in the IWRS  according to a computer-
gener ated randomization schedule.  The randomization schedule will be generated by  the 
unblinded statistician  and uploaded to the IWRS.  The randomization schedule will  be maintained 
securely within the IWRS. Patients will be randomized to Encapsulated Benzoyl  Peroxide 
Cream, 5%, or Vehicle Cream, once daily  on a 2:1 basis for twelve  (12) weeks.  
Once a patient is determined eligible for the study at the Baseline visit, the patient will be  
randomized to study product assignment by the IWRS. E ach study product carton will contain 
four pumps of the same product;  The first supplied pump in each  kit is marked A  (e.g. number  of 
pump within a kit is XXXXA), at Visit 4/ Week 4 the patient will return the pump and will be  
dispensed with the next pump which  is marked  B. At Visit 5/ Week  8, the patient  will be dispensed 
with a pump marked C. The pump marked as D is a backup pump. The patient number will be  
added  to both parts of the kit label (open part and tear -off label and to the pump label). 
18.2. Formulations  
Study Product name:  Encapsulated Benzoyl Peroxide Cream, 5% 
Sponsor name:  S5G4T-1 
Active  ingredients: benzoyl peroxide 
Inactive ingredients: see list below 
Placebo  Product: Vehicle Cream  (for study product) 
Sponsor name:  S5G4T-2 
Active  ingredients: none 
Inactive ingredients: see list below 
The inactive ingredients include:  silicon dioxide, cetrimonium chloride, polyquaternium -7, lactic  
acid,  hydrochloric acid,  polyoxyl 100 stearate,  cetyl  alcohol, cyclomethicone 5, glyceryl  
monostearate, citric acid anhydrous, sodium hydroxide, edetate disodium, glycerin, phenoxy 
ethanol, methylparaben (only in vehicle) and water.  
18.3. Study Products Packaging  and Labeling  
The study product (Encapsulated Benzoyl Peroxide Cream, 5%), S5G4T -1, and placebo for the  
study product (Vehicle Cream), S5G4T -2, will be packaged and labeled in 55- g airless pump. At 
the first 12 weeks of treatment, a double -blind technique will be used. In order to maintain the  
blind, the study product and vehicle will be suppl ied in identically -appearing  labeled  pump cartons. 
Neither the patient nor the investigational staff (sponsor, investigator, and evaluators) will know  
which  treatment a  patient  is receiving.  
The study  products w ill be shipped to sites in blocks of three  (3) products to keep  ratio 2:1 between  
study product and vehicle.  The study products will be labeled with the following: 
• Protocol Number 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  60 of 85  
 • Patient  Number 
• Kit Number 
• Pump Number 
• Patient  Initials  
• Dispense Date  
• Dispenser  Initials  
• Contains: one (1) pump of S5G4T-1 (Encapsulated  Benzoyl Peroxide) Cream,  5% or its 
Vehicle Cream, 55  g 
• Directions  for use: Apply as directed, for topical  use only. 
• Storage conditions “Store at Room Temperature  20 to 25°C (68 to 77°F). Excursions 
permitted  between 15 to 30°C (59 to 86°F).” 
• Keep  container tightly  closed.  
• Do not freeze and  do not refrigerate.  
• Keep  out of reach  of children. 
• Study product warning. “Caution: New Drug - Limited by Federal Law to Investigational 
Use”  
• Sponsor Information  
Each Study Product Kit Box will contain four (4) pumps and will carry a two- part label with a  
perforation. The tear -off section of the label will be attached to the study product dispensing log 
at the time the study product is dispensed. The other label part must remain attached to the box.  
Both label  parts  will have spaces  to enter  the patient’s  initials,  date dispensed, dispenser’s initials.  
The constant label part  shows: 
• Protocol Number 
• Patient  Number 
• Patient  Initials  
• Kit Number 
• Randomization Date  
• Contains: four (4) pumps of Encapsulated  Benzoyl  Peroxide (E-BPO)  Cream,  5% or its 
Vehicle Cream, 55  g. 
• Directions  for use: Apply as directed, for  topical  use only. 
• Storage conditions “Store at Room Temperature  20 to 25°C (68 to 77°F). Excursions 
permitted  between 15 to 30°C (59 to 86°F).” 
• Keep  container tig htly closed.  
• Do not freeze and  do not refrigerate.  
• Keep  out of reach  of children. 
• Study product warning. “Caution: New Drug - Limited by Federal Law to Investigational 
Use”  
• Sponsor Information  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  61 of 85  
 18.4. Preparation,  Dispensing and Storage Instructions 
The study product must be dispensed only to study patients  and only at study sites specified  on the 
form  FDA  1572 by authorized  personnel as  required by applicable regulations and guidelines. 
Study product will be dispensed at:  Baseline, Weeks 4 and 8.  Study product will be returned at:  
Weeks  4, 8 and 12. Study product weight will be documented in EDC  prior to dispensing and after 
return  of each pump per flow chart ( Section 13.9 and Section 5.2). 
Each Patient will be instructed on the importance of returning his or her study product at each  
designated visit. If a Patient does not return his or her study product, he or she will be instructed  
to return it at the next visit.  
The study coordinator will question the patient on history of study product use since the last visit  
and will record any missed doses (as recorded on the patient diary) in both the source documents  
and the appropriate eCRF. A patient who deviates significantly from the prescribed dosage will  
be counseled. 
Study  product should be stored  at room temperature 20 to 25°C (68 to 77°F). Excursions permitted  
between  15 to 30°C (59 to 86°F). Do not freeze or refrigerate the product. 
18.5. Dosing Instructions 
Topical  application  of study  product will be made to the face once daily  at approximately the same  
time of the day,  for a period of twelve  (12) weeks.  Study product will be applied as  a thin coating  
that is gently  rubbed in to the skin. 
Each patient will receive both verbal and written instructions (see Appendix 1) as to the proper  
dosing and study product application techniques. Patients  will be instructed  to apply the study product for 12 weeks, once a day  after cleansing. No 
time interval between dosing  and meals or any  other activity  is specified.  
Patients will cleanse their face with the given cleanser or sponsor approved cleanser using only 
the hands and pat dry with a soft clean towel. Patients will use a “pea -size” amount for each area 
of the face (chin, left cheek,  right cheek,  nose, left forehead  and right forehead).  The Patient  should 
gently rub the cream into the skin. This amount of cream should be sufficient to cover the area on the face excluding the mouth, eyes, inside the nose, and lips. The Patient should wash his/her  
hands after application but should not wash face at least 2 hours after study product applic ation. 
Patients  should wait at least 30 minutes  before  applying moisturizer/sunscreen  after application  of 
study product to the face. During the trial that investigators remind patients to avoid exposure to  
sunlight and sunlamps and to wear sunscreen  when  sun exposure cannot be avoided. 
The Patients will be instructed to continue using the same supplied/approved facial cleanser and not to change
 products during the study. At each visit,  Patients  are to be asked  if they have changed  
their cleansing routine. The supplied/approved cleanser and moisturizer/sunscreen should be  
applied according to the directions on the pump. Facial makeup (non -medicated) may be applied  
according to the patient’s normal daily routine (but not prior  to 30 minutes after study product  
application); however, patients should be instructed not to apply the moisturizer or sunscreen or  
combination of them or wear make -up during study visits as it may interfere with the evaluator’s  
assessments.  No other products should be used on the face.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  62 of 85  
 Pump usage will be demonstrated by the site personnel on a sample pump at the clinic to help  
assure the patient understands the procedure. The patient will be provided a set of instructions  
(Appendix 1) that includes study reminders and restrictions as described in this protocol. Patients  
will be instructed to bring the study product to each visit and to not apply study product one hour  
prior to the study visit.  Patients  should be instructed  to store  the study product at room 
temperature,  not in the refrigerator or freezer  and informed  that the test article  may bleach  colored  
fabric.  
18.6. Study Product Accountability  and Study Records  at Sites  
Upon receipt of the clinical supplies, the study staff will conduct a complete inventory of study  
products and assume responsibility for their storage and dispensing. In accordance with federal  
regulations, the Investigators must agree  to keep  all study products in a secure,  temperature-
controlled location with restricted  access.  
All supplies sent to the Investigators will be accounted  for and in no case used in any unauthorized 
manner.  All used and unused study product will be appropriately inventoried by the clinical site, 
and verified by the clinical monitor.  
Study product will be weighed before  dispensing and upon return  and weights will be recorded  on 
the appropriate source document and eCRF. 
18.7. Return  and Destruction  of Study Product Supplies 
Upon completion or termination of the study, all remaining pumps (in kits) must be appropriately 
inventoried and returned to Sponsor or designee by a traceable method.  All missing pumps of  
study products must be explained on the completed  Clinical Supplies Return  Form.  The study site 
must keep a copy of the Clinical Supplies Return  Form  in the study file. 
18.8. Additional Supplies Provided by Sponsor 
• Regulatory study file system  (Investigator Binder) 
• Urine  pregnancy  test kits 
• Cleanser  
• Moisturizer/sunscreen  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  63 of 85  
 19. STATISTICAL  CONSIDERATIONS  
19.1. General  Statistical Methods 
All statistical processing will be performed using SAS® version 9.3 or later unless otherwise  
stated.  Statistical significance will be based on two -tailed tests of the null hypothesis resulting in  
p-values of 0.05 or less.  These  methods are intended to analyze the results  of the study. 
The primary method of handling missing efficacy data will be based on estimation using the  
method of Markov Chain Monte Carlo (MCMC) imputation. This method provides robust  
estimation when the pattern of missingness is arbitrary.  Additionally, the estimation will be done  
for each treatment group separately so that the pattern of missingness for one group does not  
influence the estimation  of missing  data for another group. Groups of complete  datasets  following 
the estimation will be concatenated to form analysis datasets for the comparative analyses and  
subsequent imputation  result  inference with SAS PROC  MIANALYZE.  Descriptive  statistics  will 
also be derived  from the  multiply  imputed datasets.  
Additionally, a model -based multiple imputation process will be used as a sensitivity analysis to  
the MCMC imputation.  Finally, the absolute change in lesion count will be analyzed using a  
repeated measures ANCOVA for lesion count data or a repeated measures logistic regression  
model (generalized  estimating  equations) for the dichotomized  Investigator’s Global Assessment,  
IGA.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a separate  
document. The SAP will be finalized prior  to unblinding of the study treatments.  
19.1.1. Patient  Disposition  
A tabulation of patient disposition will be provided. The tabulation will include the numbers of  
patients who enter the study, complete the study, and discontinue the study. The reasons for  
discontinuation will be  included. 
19.1.2. Demographics  and Baseline  Characteristics  
Patient demographic and baseline characteristics will be summarized by treatment group for the  
ITT, PP, and safety populations. For continuous variables (e.g. age) comparisons among the two  
treatment groups will be conducted using a two- way analysis of variance (ANOVA) with factors  
of treatment group and analysis center (see Section 19.4.6 for definition of “analysis center”). 
Ethnicity and race will be analyzed with a Cochran -Mantel -Haenszel test stratified by analysis  
center.  Past and current medical conditions, as well as history of disease will be presented in a  
data listing.  
19.1.3. Protocol Deviations 
All protocol deviations will be reported to the sponsor and recorded throughout the study. A 
tabulation  of protocol deviations will be presented in a data listing.  
19.1.4. Analysis Populations  
Approximately 350 male and female patients at least  18 years of age with moderate or severe  
papulopustular rosacea with 3 or 4 [moderate to severe] on the IGA scale will be enrolled and  
randomized  in the study with a  2:1 randomization ratio, it is anticipated that: 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  64 of 85  
 • 234 patients will be randomized to receive S5G4T -1, Encapsulated Benzoyl Peroxide  (E-
BPO)  Cream, 5%  
• 117 patients  will be  randomized to receive S5G4T -2, Vehicle Cream  
The ITT population will consist of all randomized patients who were dispensed study product.  
The safety  population will be comprised  of all randomized  patients  who are presumed  to have used 
the study product at least  once and who provide at least one post- baseline safety  evaluation. 
An intent -to-treat (ITT) analysis will be conducted on all study patients. A per-protocol (PP)  
analysis will also be conducted. Patients will be eligible for the PP analysis if they complete the  
12-week evaluation without noteworthy study protocol violations (i.e., any patient or investigator  
activity that could have possibly inter fered with the therapeutic administration of the treatment or  
the precise evaluation of treatment efficacy).  The PP population will include patients in the ITT  
population who do not meet any of the following criteria:  
• Failed  any of the inclusion/exclusion criteria;  
• Have taken any  interfering  concomitant medications; 
• Did not attend the Week  12 Visit;  
• Missed  more  than 1 post baseline study visit prior  to Week 12  
• Have not been compliant with the dosing regimen (i.e., Patients may not miss more than  
five consecutive days of dosing and must take 80 to 120% of expected doses. The number 
of expected  doses will be determined  for each patient  based  on the length of their 
participation  in the study); 
• Out of visit window (± 4 days) at  the 12- week  Visit.  
Patients that discontinue from the study due to an adverse event related to study treatment or  
documented lack of treatment  effect  will be included  in the PP population. Data for these subjects  
will not be imputed by multiple imputation but rather their data will be imputed with values  
consistent with their status as treatment failures. Prior to breaking the blind, other additional  
criteria may be added to the list to accommodate for unforeseen events that occurred during the  
conduct of the trial that result in noteworthy study protocol violations. 
19.2. Study Product Evaluations  and  Analyses 
Inflammatory lesion count will be recorded for each patient at the Baseline and at Weeks 2, 4, 8  
and 12. The absolute and percent change from baseline of inflammatory lesions will be derived  
for each patient at Weeks  2, 4, 8 and 12. 
The IGA will be recorded for each patient at the Baseline visit and site visits at Weeks 2, 4, 8 and 
12 (End of Study). The IGA will be dichotomized into “success” and “failure” at Weeks 2, 4, 8  
and 12 with a patient considered a success for those visits if the IGA is at least 2 grades less than  
baseline and are Clear or Almost Clear.  
The Rosacea Erythema assessment, and Telangiectasia assessment will be recorded at Baseline  
and at Weeks 2, 4, 8 and 12. 
Patients will be asked to complete Patient Reported Outcome, PRO, questionnaires at appropriate time points.  
All statistical analysis  will be conducted for both PP and ITT population. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  65 of 85  
 19.3. Assessment  of Efficacy  
Primary,  secondary, and supportive efficacy  analyses  will be conducted on the ITT (primary) 
population. Primary  efficacy  analyses will be  conducted on the PP (supportive) population. 
19.3.1. Primary  Efficacy  
There are two co-primary  efficacy  endpoints: 
• Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost clear”  
(1) in the IGA relative  to Baseline at  Week  12. 
• Absolute change in inflammatory  lesion counts from baseline to Week 12. 
19.3.2. Secondary  Efficacy  
The secondary efficacy  endpoints will be the following: 
• Percent  change in inflammatory  lesion  count from  baseline  to Week  12 
• Absolute change in  inflammatory  lesion  count from baseline to Week  8 
• Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost clear”  
(1) in the IGA relative  to Baseline at  Week  8 
• Absolute change in inflammatory  lesion count from baseline to Week  4 
• Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost clear”  
(1) in the IGA relative  to Baseline at  Week  4 
• . 
19.3.3. Supportive  Efficacy  
Supportive efficacy  endpoints include the following: 
• Percent  change in  inflammatory  lesion  count at  Week 8  
• Percent  change in  inflammatory  lesion  count at Week 4  
• Mean  change comparison  in PAPSS item 1 (burning) between  groups from  Baseline to 
Weeks  4, 8 and 12 
• Mean  chan ge comparison  in PAPSS item 2 (itching)  between  groups from  Baseline to 
Weeks  4, 8 and 12 
• Mean  change comparison in PAPSS item 3 (redness)  between  groups from  Baseline to 
Weeks  4, 8 and 12 
• Mean  change comparison in PAPSS item 4 (bumps) between  groups from  Baseline to 
Weeks  4, 8 and 12 Rosacea erythema assessment  at Week 12  
• Telangiectasia assessment  at Week 12  
• The proportion of patients  in treatment  relative  to control who report  at least “minimally  
improved” as measured by  the PGI -C at Week 12  
• Mean  change in  the components of the PAPI score between  groups from  Baseline to  
Week 12  
• Proportion of patients  in the treatment  relative to control achieving  a three -point 
improvement in the components of the PAPI  score from Baseline  to Week  12 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  66 of 85  
 • Patient  Global Impression  of Symptom Severity  (PGI -S) at Week 12  
• Patient  Global Impression  of Treatment  Satisfaction  (PGI -TS) at Week  12 
• A set of cumulative distribution function (CDF) curves will be generated to allow for the  
evaluation of within- person change by treatment group. Specifically, 5  plots will be  
generated showing the change from baseline to Week 12 [and/or other, earlier time points  
if so desired] by the cumulative percent  of subjects  for each  of the treatment  arms  (change 
on the x -axis will be  expressed as  absolute change) on: 
o PAPSS total scale scores;  
o PAPSS item 1 (burning) scores; 
o PAPSS item 2 (itching) scores;  
o PAPSS item 3 (redness) scores;  and 
o PAPSS  item 4 (bumps) scores  
19.4. Statistical Hypothesis Testing  
19.4.1. Test of Superiority  for Lesion  Count  Variables  
This section provides the basic model and statistical approach which is used in combination with 
the multiple imputation procedures described in Section 19.4.6. Tests of superiority for the  
absolute change from Baseline in inflammatory lesions will be based on non- parametric methods  
consistent with the statistical assumptions required to support the analyses. Specifically, the tests 
of superiority will be based on ranked data submitted to an ANCOVA with factors of treatment  
and analysis center and the respective Baseline lesion  count as a covariate.  
For informational purposes, a skewness  test, based  on the methods presented  by Zar 1984, will be 
applied  to the residuals  resulting  from  an ANCOVA using the untransformed  lesion  count  data. A 
two-sided  p-value for the skewness  test significant at 0.05 would validate the use of the non-
parametric method.  The results of a non-ranked ANCOVA with factors of treatment and  analysis 
center and the respective Baseline lesion count as a covariate will also be presented for  
informational purposes. 
19.4.2. Test of Superiority  for IGA  
The IGA will be dichotomized  into “success” and “failure” with a patient  considered a success  for 
those visits if the Investigator’s Global Assessment is at least 2 grades less than Baseline and  
“Clear” or “Almost Clear”.  The analysis of the dichotomized IGA will be based on a logistic  
regression  test with  factors of  treatment group and analysis  center.  
19.4.3. Test of Superiority  for Secondary  Efficacy  and Control of Multiplicity  
Appropriate descriptive  statistics  will be computed for all Secondary Efficacy  parameters.  
Additionally, all inferential testing will follow the methods for the primary lesion count analyses  
as well as those  for the  dichotomized IGA success  rates (as  appropriate). 
The overall Type I error will be controlled by requiring the two co- primary efficacy endpoints to  
be statistically  significant.  Specifically,  failure  of either  one of the primary  efficacy  endpoints will 
invalidate  the statistical significance  of the secondary  efficacy  endpoints. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  67 of 85  
 A stepwise process will be conducted for testing the secondary efficacy endpoints in order to  
control for multiplicity.  These tests will be performed for only the ITT population. The testing  
process will terminate whenever a statistical test for a step is not significant.  All subsequent tests  
for the remaining steps will be considered not significant. The order of testing is provided in  
Table 6.  
 
Table 6: Process  for Testing  the Secondary  Efficacy  Endpoints  
 
Step 
Number  Secondary  Endpoint  
1 Percent  change in inflammatory  lesion  count  from  baseline  to Week  12 
2 Absolute  change  in inflammatory  lesion  count  from  baseline  to Week  8 
3 Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost  clear” (1) in 
the IGA relative to  Baseline at  Week  8 
4 Absolute  change  in inflammatory  lesion  count from  baseline  to Week  4 
5 Proportion of patients  with the primary  measure of success  “Clear” (0) or “Almost  clear” (1) in 
the IGA relative to  Baseline at  Week  4 
 
19.4.4. Supportive  Efficacy  Analyses 
Appropriate descriptive statistics  will be computed for all Supportive Efficacy  parameters.  
Additionally, inferential testing for the following endpoints will use an ANOVA with factors of  
treatment, analysis center and the respective Baseline score. The overall Type I error will be 
controlled by the Benjamini-Hochberg method. Missing values will not be imputed. 
• Mean  change comparison  in PAPSS item 1 (burning) between  groups from  Baseline to 
Week 12  
• Mean  change comparison  in PAPSS item 2 (itching)  between  groups from  Baseline to 
Week 12  
• Mean  change comparison in PAPSS item 3 (redness)  between  groups from  Baseline to 
Week 12  
• Mean  change comparison in PAPSS item 4 (bumps) between  groups from  Baseline to 
Week 12  
19.4.5. Exploratory Endpoint  
The mean change in RosaQoL subscale scores from  Baseline to  Week 12.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  68 of 85  
 19.4.6. Pooling Analysis 
The clinical study will be conducted under a common protocol for each investigational site with  
the intention of pooling the data for analysis. Every effort will be made to promote consistency in 
study execution at each investigational site. The study is intended to be conducted in a manner  
such that a minimum of 5 patients will be enrolled in each treatment arm for any investigator.  In 
the event  that there  are too few patients  in a treatment  arm for an investigator, then this 
investigator's data will be combined to achieve the desired sample size minimum per arm.  The 
combining of investigator's data will be accomplished by taking the investigator with the smallest enrollment and  combining it with the investigator with the largest  enrollment.  If there is a further 
need  to combine data,  then the data of the investigator with the second  smallest  enrollment will be 
combined with the investigator's data which had the second largest enrollment and so on. This 
process  will continue for all  investigators who did not have a minimum of 5 patients  per treatment  
arm. The process of combining investigator data that have insufficient patients per treatment arm  
will result in redefining the groups of investigators for the purposes of statistical analyses. These  
combined groups will be referred to as "analysis centers" in the statistical analyses based on  
ANCOVA and stratified  logistic testing.  
Prior to investigating the treatment effect within the analysis centers, the magnitude of the site  
mail effect  will be investigated  to determine  if the main  site-to-site variability  is such that it could 
mask the analysis center effects.  Thus, if computationally possible, a one -way ANCOVA (for  
lesion count variables) or a logistic regression analysis (for IGA) with a factor of site will be  
conducted prior to pooling. If the data structure  interferes  with the logistic  regression, a descriptive  
analysis of the site effect will be undertaken.  Conclusions appropriate to the findings of this step  
will be presented.  
The consistency of treatment response will be investigated across the analysis centers subsequent  
to combining the data as described above.  Statistical tests will be conducted to identify if there  
are extreme analysis centers that could affect the interpretation of common statistical and clinical  
conclusions. An analysis center by treatment interaction will be included in the primary varia ble 
analyses to test for parallel treatment effect at an alpha level of 0.10.  Change from baseline in  
inflammatory lesions will be analyzed with an ANCOVA (unranked or ranked) with factors of  
treatment,  analysis  center,  and treatment  by analysis  center  interaction  and the respective baseline  
lesion  count variable  as a covariate.  For the purpose of testing  consistency  of treatment  response, 
the dichotomized IGA will be analyzed with a logistic regression procedure with factors of  
treatment, analysis center, and treatment by analysis center interaction.  Further examination will  
follow for any variables that have a significant ANCOVA or logistic regression interaction term. In the event that the ANCOVA or logistic regression interaction (referred to henceforth as the  
"appropriate  test")  p-value is less than or equal  to 0.10, a sensitivity  analysis  that excludes  analysis  
centers with the extreme efficacy result will be performed to determine the robustness of the  
treatment effect.  On the other hand, if the outcome of the appropriate test has a p -value greater  
than 0.10, then the conclusions from  the pooled data will be considered to be  free of the impact  of 
extreme analysis centers.  
The first step in conducting a sensitivity analysis is to identify the extreme analysis center or  
cen
ters that contribute to the statistical significance of the appropriate test.  The process involves  
submitting subsets of analysis centers to the appropriate test and observing the appropriate test  p-
value for the subset. Subse ts with p -values greater than 0.10 for the appropriate test are  
considered  homogeneous. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  69 of 85  
 The search for an extreme analysis center begins by analyzing all subsets that can be created by  
excluding one analysis center.  If one or more of the subs ets result in an appropriate test p -value 
greater than or equal to 0.10, then the analysis center excluded from the subset with the largest  p-
value for the  appropriate test is deemed  to be the extreme analysis center.  
If all appropriate test subset p -value s are less than or equal to 0.10, then the process will analyze  
the appropriate test for  all subsets that can be created  by excluding two analysis  centers.  If  one or 
more  of these  subsets generate appropriate test  p-values  larger  than 0.10, then  the analysis  centers  
excluded  from  the subset with the largest  appropriate test p-value are deemed  the extreme  analysis  
centers.  
Thus, the process of identifying the extreme analysis centers will continue in a stepwise manner  
by first excluding one, then two, then three,  etc.,  analysis centers  until the appropriate test p-value 
exceeds  0.10. 
Once the extreme analysis center or centers have been identified, then the treatment p -values of  
the remaining analysis centers will be computed.  Inferences will be drawn from the treatment  p-
value, as well as any pertinent observations regarding the extreme analysis center or centers.  
Additionally, it is noted that this process excludes patients from the analysis in a non-random 
manner  and has an unpredictable impact  on the power  of the treatment effect  test. In the event  that 
the treatment  effect  of the remaining  subset is not statistically  significant,  due consideration of the 
post-hoc aspects  of the process  will be given when  the results  are interpreted. Conclusions will be 
presented  by the sponsor as appropriate to the findings of the sensitivity  analysis.  
19.4.7. Missing  Efficacy  Data  Imputations  
19.4.7.1. Lesion  Count Variable  Missing  Data  Imputation  
Missing Week 12 data will be estimated by multiple imputation and subsequently analyzed.  
Missing  lesion  count data will be derived  for the analysis  using the method of Markov Chain  Monte 
Carlo (MCMC) multiple imputation. The pattern of missing observations in each treatment group  
cannot influence  the missing  value estimation  in the other because the imputation  will be 
conducted independently for each treatment group. 
Multiple imputation and subsequent analysis will involve 3 distinct phases with these principal  
task
s: 
1. Create  a data set  of patients,  one for each  treatment group, with observed values  and those 
needing estimation by MCMC. The missing lesion count values in each data set will be  
filled in using the MCMC method 5 times to generate 5 data sets.  The resulting data sets  
for each treatment arm will be combined into one complete data set for each imputation.  
Syntax: 
proc mi data=datain out=dataout seed=&seed. nimpute=5 
<options>; 
where trtpn=(1, or 2); mcmc chain=multiple; 
var baseline week2 week4 week8 week12; 
run; 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  70 of 85  
 2. For each complete data set, the variable of interest for baseline minus the Week 12 value 
will be computed. Each complete data set will be analyzed as specified for the particular  
analysis.  
3. The results  from  these analyses  will be combined into a single inference  using SAS PROC  
MIANALYZE.  
A total of 6 random seeds are needed to impute inflammatory lesion counts. These random seeds  
have been pre- specified  by using a random number generator:  
• Inflammatory  Lesion  Counts Week  12 S5G4T-1: Seed =  2046620966 
• Inflammatory  Lesion  Counts Week  12 Vehicle:  Seed  = 693843173 
• Inflammatory  Lesion Counts Week 8 S5G4T-1: Seed =  385596352 
• Inflammatory  Lesion  Counts Week  8 Vehicle:  Seed =  386411964 
• Inflammatory  Lesion Counts Week 4 S5G4T-1: Seed =  796550211 
• Inflammatory  Lesion  Counts Week  4 Vehicle:  Seed =  40534656 
 
19.4.7.2. IGA Missing  Data  Imputation  
A similar procedure will be used for the analyses based on proportion of IGA successes wherein 
the ANCOVA analysis is replaced with a logistic regression analysis.  Specifically, missing 12  
week IGA values from which the dichotomized IGA is derived will be estimated by (MCMC).  
The pattern of missing observations in each treatment group cannot influence the missing value  
estimation  in the other because the imputation  is being conducted independently for each treatment 
group. 
The missing 12- week IGA values will be derived for the analysis using the method of Markov 
Chain Monte Carlo (MCMC) multiple imputation.  Multiple imputation and subsequent analysis  
will involve 4 principal tasks: 
1. Create  a data set,  one for  each  treatment group, of patients  with observed values and those 
needing estimation by MCMC. The missing IGA values in each data set will be filled in  
using the MCMC method 5 times to generate 5 data sets.  The resulting data sets for each  
treatment  arm will be combined into one complete  data   set   by   imputation.  
Syntax: 
proc mi data=datain out=dataout seed=&seed. nimpute=5 
<options>; 
where trtpn=(1, or 2); mcmc chain=multiple; 
var baseline week2 week4 week8 week12; 
run; 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  71 of 85  
 2. For each complete data set, the dichotomous success rate (clear or almost clear with a 2-
point change from baseline) will be computed. The 12 -week estimated global values  will 
be rounded to the nearest integer value prior to evaluating the success rate.  Each  
complete  data set will be analyzed  with a logistic  regression  with factors  of treatment  group 
and analysis center.  
3. The results  from  these analyses  will be combined into a single inference using SAS PROC  
MIANALYZE.  
A total of 2 random seeds  will be needed  to impute  IGA for the two treatment  groups. Those 2 
random seeds have been  pre-specified by using a random number generator:  
• IGA Week  12 S5G4T-1: Seed  = 712066910 
• IGA Week  12 Vehicle:  Seed  = 1200150465 
• IGA Week  8 S5G4T- 1: Seed  = 1871392013 
• IGA Week  8 Vehicle: Seed  = 1866129897 
• IGA Week  4 S5G4T- 1: Seed  = 301965746 
• IGA Week  4 Vehicle: Seed  = 812607204 
19.4.8. Sensitivity  Efficacy  Analyses 
19.4.8.1. Sensitivity  Analyses  for Absolute Change  in Lesion  Count  
The first sensitivity analysis for absolute change in lesion count will use a repeated measures  
ANCOVA,  with treatment,  analysis  center,  and visit (i.e., Weeks 2,  4 and 8) as independent factors  
and a covariate of baseline lesion  count. In this analysis, data  from  all post- baseline visits  will be 
included with no imputation for missing data.  
The second sensitivity analysis will use the model based multiple imputation method to impute  
missing  data for the absolute change  in lesion  counts at Week 12. Although the full details  will be 
presented in the Statistical Analysis Plan (SAP), the multiple imputation will involve 4 principal  
tasks:  
1. Missing values will be filled in 5 times to generate 5 complete data sets.  Th e imputation  
model used will be an ANCOVA with factors of treatment group and analysis center, and 
a covariate of baseline lesion count (i.e., the imputation model will be the same as the  
analysis model). Appropriate modifications will be made should the analysis be based on  
a non- parametric method.  
2. Each  complete  data set will be analyzed  with an ANCOVA with factors  of treatment  group, 
and analysis center, and  a covariate of  baseline lesion  count. 
3. Results  from  these analyses  will be combined into  a single inference.  
19.4.8.2. Sensitivity  Analyses  for IGA 
The first sensitivity analysis for the dichotomized IGA success will use a repeated measures  
logistic regression model (generalized estimating equations), with dichotomized IGA success as  
the dependent variable and treatment, a nalysis center,  and visit (i.e., Weeks 2, 4 and 8) as  
independent factors.  In this analysis, data from all post -baseline visits will be included with no  
imputation for missing  data.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  72 of 85  
 The second sensitivity analysis will use the model based mul tiple imputation method to impute  
missing data for the dichotomized IGA data. Although the full details will be presented in the  
SAP,  the multiple imputation will involve 4 principal tasks:  
1. Missing values will be filled in 5 times to generate 5 complete data sets.  The imputation  
model used logistic  regression with factors  of treatment  group and analysis  center  (i.e., the 
imputation  model will be  the same as the analysis model).  
2. Each complete data set will be analyzed with a logistic regression a factors of treatment  
group and analysis center. 
3. Results  from  these analyses  will be combined into  a single inference.  
19.4.9. Subgroup Analyses 
Subset analyses will be conducted for the ITT populations for the subgroups baseline global  
severity, gender, age, ethnicity, race, and geographic region. Age will be dichotomized to less  
than the median age of patients and greater than or equal to the median age of patients. Subset 
analyses  will be conducted on the variables  absolute change from  baseline in inflammatory  lesions 
at Week 12 as well as the dichotomized global severity score at Week 12.  These analyses will  
contain only descriptive statistics.  
19.5. Assessment  of Safety  
Safety will be evaluated by tabulations of adverse events (AEs), Cutaneous Safety Assessments  
for dryness and scaling, assessments for scores (erythema and telangiectasia) and Patient Global  
Impression of Treatment Side -Effects (PGI -SE) will be presented with descriptive statistics at  
Baseline and at Weeks 2, 4, 8 and 12 for each treatment group. Frequencies and percentages for  
each outcome category will be included in these  statistics.  Mean values will be presented  
graphically  by week and  treatment  group. 
19.6. Adverse Events 
All adverse events occurring during the study will be recorded and classified on the basis of  
MedDRA  terminology. Descriptions of AEs will include the date of onset, the date the AE ended, 
the severity of the AE, the relationship to study product, the action taken regarding study product  
usage, the action taken to treat the AE, and the outcome. All reported treatment- emergent AEs  
(TEAEs) will be summarized by the number of Patients reporting AEs, system organ class,  
severity,  seriousness, and  relationship  to study product. TEAEs  are those AEs  with an onset  on or 
after the date of  the first  study product application.  
Adverse events  will be summarized  by treatment  group and severity.  Each  patient  will be counted 
only once within a system organ class or a preferred term by using the adverse events with the  
highest severity  within each category.  
Adverse events will be summarized by treatment group and relationship to study product.  Each  
patient will be counted only once within a system organ class or a preferred term by using the  
adverse events with the greatest relationship within each  category.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  73 of 85  
 Comparisons among treatment groups will be made by tabulating the frequency of patients with 
one or more AEs (classified into MedDRA terms) during the study. The Fisher’s Exact test will  
be used to compare the proportion of patients in each treatment group who report any adverse  
event at a significance level of 0.05. The specific system organ classes and preferred terms  
analyzed will be those that are reported by at least one percent of the patients in any treatment  
group. 
All information pertaining to AEs noted during the study will be listed by patient, detailing  
verbatim given by the investigator, preferred term, system organ class, start date, stop date,  
severity,  actions taken,  and drug relatedness.  The AE onset will also be shown  relative (in number  
of days) to the day of initial dose of  the randomized study product. 
Serious adverse events  (SAEs) will  be tabulated  by patient within  treatment  groups. 
In addition, a list of patients  who discontinued from  the study and a list of patients  who experienced  
SAEs  will also be provided. 
19.6.1. Vital  Sign Measurements  
Vital signs as well as changes from Baseline in vital sign measurements will be summarized with  
descriptive statistics for  each treatment group at all  applicable study visits.  
19.6.2. Concomitant Medications  
All previous therapies and concomitant medications will be classified based on terminology from  
the WHO  Drug  Dictionary.  Previous therapies  and concomitant medications  data will be presented  
in data listings.  
19.7. Sample  Size Determination  
The following power calculations  are based  on the observed  Week  12 results  of the Phase 2 study, 
SGT -EBP01 -09. This study was a three -arm trial including E -BPO Cream, 1% and 5%, and  
Vehicle in the Treatment  of Rosacea.  Estimates  from  the E- BPO  Cream,  5% arm were  used in the 
power assessments.  The anticipated  randomization ratio is 2:1 for E- BPO  Cream,  5% and Vehicle,  
respectively.  The computations were performed  with nQuery Advisor Version 7.0 using a two-
sided  test with a  statistical significance  value of 0.05. 
A sample size of 86 in the E -BPO Cream, 5% and 43 in the Vehicle has group has 95% power to 
detect  a statistically  significant difference in the proportion of patients  who have at least a 2-grade 
reduction at Week 12 from baseline in IGA and are Clear or Almost Clear.  The estimated  
percentages with a 2 -grade reduction at Week 12 from baseline in the IGA and Clear or Almost  
Clear  are 53.3% and 20.0% for the E -BPO Cream  and Vehicle,  respectively.  
A sample size of 200 in the E -BPO  Cream, 5% and 100 in the Vehicle group has 95% power to 
detect  a statistically  significant  difference in inflammatory  lesions. The estimated  absolute change 
from  baseline in  treatment  means  were  -14.1 and -7.4 for the  E-BPO Cream  and Vehicle,  
respectively,  with a standard deviation of 6.70 and 17.24, respectively. 
The sample  sizes  above will be increased  to give a planned  enrollment of 234 in the E- BPO  Cream,  
5% group and 117 in the Vehicle group since the Phase 3 trial is expected to enroll patients who  
are as a group more severe than those of the Phase 2 trial. This is a consequence of some changes 
in the inclusio n criteria.  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  74 of 85  
 20. ADMINISTRATIVE  CONSIDERATIONS  
20.1. Protocol Compliance 
The IRB -approved protocol must be followed except in the case of a change that is intended to 
eliminate  an immediate  risk to patients.  All protocol deviations must be documented in the source  
documents and in the comment CRFs.  
20.2. Protocol Revisions 
Sponsor or designee must prepare all protocol revisions. All protocol amendments must receive  
IRB approval prior to implementation.  All administrative  letters  must be submitted  to the IRB for 
their information. Copies of all correspondence with the IRB regarding this  study must be  sent to 
Sponsor or CRO designee. New or altered consent forms required by the IRB due to a protocol  
revision must be signed by all patients currently enrolled in the study and must be used for any 
subsequent patient enrollment.  
20.3. Protocol Monitoring 
Representatives  of Sponsor must be allowed to  visit all study sites,  to review  study records and  to 
directly compare them with source documents (inc luding, but not limited to patient and hospital  
records), to discuss the study conduct with the investigator and study staff; and to verify that the  
investigator, study staff and facilities  remain  acceptable  for the conduct of the study. 
Representatives of government regulatory authorities (i.e., FDA) may also evaluate the study  
records,  source documents, investigator, study staff, and facilities.  
The investigator must immediately notify Sponsor of any audits by any regulatory agency, and  
must promptly  provide copies of any  audit reports. 
20.4. Required  Study Documents 
The investigator must provide the following documents to Sponsor or CRO designee before any  
patients are enrolled and/or study product may  be shipped to the study site: 
• The signed INVESTIGATOR  PROTOCOL  ACKNOWLEDGEMENT  page  from  the 
Sponsor and  IRB approved protocol. 
• Documentation of IRB  approval of the protocol, informed  consent form,  any other written  
information  provided to patients and any recruitment advertisements.  
• A copy of the IRB  approved informed consent form 
• A current  IRB assurance number  and/or a membership  roster.  
• A completed,  signed and  dated  Form FDA  1572. 
• The appropriate financial  disclosure documentation. 
• A current signed and dated curriculum vitae and a copy of the current medical license for  
the investigator and sub-investigators listed on the Form  FDA  1572. 
• The signed agreement between the investigator and Sponsor, or designee, and related  
fi
nancial information for the study (this file is confidential and currently FDA has no  
authority to review  this information.  Keep this information in a separate file).  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  75 of 85  
 20.5. Electronic  Case Report Forms  (eCRF)/Source Documents 
Electronic case report forms (eCRFs) called also electronic data capture (EDC) system, will be  
used for recording all data from source documents for each patient. Source documents are the 
point of first entry for  all data collected.  Whenever  possible, an original recording  of an 
observation should be retained as source document. 
The investigator will ensure that the eCRFs  are properly and completely  filled  in. The eCRFs  must  
be completed for all patients who have signed an informed consent form. The eCRFs will be  
monitored against source documents. If data in the eCRF is not duplicated in a source document, 
a source document should be created  and maintained  by the site to capture that information.  Source  
documentation for patients includes but is not limited to the physician’s patient records, diaries,  
photographs. All source documents will be maintained at the  study site. 
The Investigator or delegate may enter corrections in the eCRFs, which will create an auditable 
history of all changes and by whom they were made. The final eCRF will be approved by the  
Investigator by electronic  signature. 
20.6. Reports to the IRB/Ethics  Committee  (EC)  
Before  study initiation,  the investigator must have written  and dated  approval  from  the IRB for the 
protocol, consent  form,  patient  recruitment  materials  /process  (e.g., advertisements),  and any other 
written information to be provided to patient. The investigator should also provide the IRB with  
a copy of the Investigator’s Brochure and/or package insert. The investigator should provide the  
IRB with reports, updates, and other information (e.g., safety updates, protocol amendments, and administrative  letters) according  to regulatory requirements  or Institution procedures. 
20.7. Quality  Assurance Audits  
Representatives from Sponsor and/or a third party selected by Sponsor may conduct a quality  
assurance audit of this study. During the audit, the Investigator must provide the auditor with 
direct  access to all relevant  documents and discuss any findings with the  auditor. 
In the event  of an  inspection by the Food and  Drug  Administration  or other regulatory authorities,  
the Investigator will notify the Sponsor /CRO  as soon as possible of such notice and must give the 
inspector direct  access to  relevant documents and  discuss any  findings with the inspector. 
20.8. Records  Retention  
The investigator must maintain records of the study product disposition, copies of the case report  
forms and all source documents for the maximum period of five years after NDA approval as  
required by Sponsor. The investigator must contact Sponsor prior to destroying any records  
associated  with this study. 
If the location of the study files changes from the address noted on the FDA Form 1572, written  
notif
ication of the new location must be given to Sponsor. If the investigator withdraws from  
participation  in the study the records  shall  be transferred  to a mutually  agreed -to designee.  Written  
notification  of such a transfer must be  given to Sponsor. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  76 of 85  
 21. REFERENCES 
Breneman D.,  Savin R., VandePol C., Vamvakias G.,  Levy S., Leyden J. Double-blind, 
randomized, vehicle -controlled clinical trial of once -daily benzoyl peroxide/clindamycin topical  
gel in the treatment of patients  with moderate to severe  rosacea.  Int. J of Derm.  2004; 43(5):381-
387. 
Jansen  T. and Plewig G. Rosacea:  classification  and treatment.  JR Soc Med.  1997; 90(3):144- 150. 
McDonnell JK and Tomecki KJ. Rosacea:  an update.  Clev  Clinic  J Med.  2000; 67(8):587-590. 
Montes LF., Cordero AA., Kriner J., Loder J., Flanagan AD.  Topical treatment of acne rosacea 
with benzoyl peroxide acetone gel.  Cutis 1983; 32(2):185-190.  
Yamasaki K.,  Di Nardo A.,  Bardan A., Murakami M.,  Ohtake T.  Coda A., Dorschner RA., 
Bonnart C., Descargues P., Hovnanian A., Morhenn VB. and Gallo RL. Increased serine protease 
activity  and cathelicidin  promotes skin inflammation in rosacea.  Nat. Med.  2007; 13:975-980. 
Zar, JH.  Bio-statistical analysis, 1984 2nd ed. Englewood Cliffs (NJ) Prentice -Hall.  (Available 
upon request).  
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  77 of 85  
 APPENDIX  1: PATIENT  INSTRUCTION SHEET 
Please follow these instructions carefully.  Contact the study staff at the telephone number noted 
below if  you have any  questions about the study: 
 
 
Contact:  At: 
 
 
STUDY PRODUCT  APPLICATION:  
• At first application, priming  is required. 
• Apply the cream once a day every  day during the study period [twelve (12) weeks].  
• Wash  your face gently with the mild cleanser  provided by the doctor or by study approved 
cleanser  for this study from the  sponsor and water. Rinse thoroughly and gently pat dry. 
• A thin coating of study product should be applied once daily (preferably at the same time  
each day) to the entire face during the study period [twelve (12) weeks].  
• Apply one gentle pump application of test material from pump onto the tip of your finger  
the size of a pea for  each area of the face (chin, left cheek, right cheek, nose, left forehead  
and right forehead),  as instructed  at your first study visit.  
• Apply the cream  on each area  of the face as evenly  as possible and gently  rub into the skin. 
Each pea- size amount should be used to evenly cover the following parts on your face:  
chin, left cheek, right cheek, nose, left forehead and right forehead excluding the mouth,  
eyes and lips. 
• Do NOT  treat specific lesions but rather  the entire  face.  
• Be sure to  wash  your hands after you apply the study product. But do not wash  your face 
for at least  two hours after you apply study product. 
• Wait  for at least 30 minutes  before  applying the moisturizer/sunscreen  provided by the 
doctor for this study. 
• If applicable,  wait  at least  30 minutes  before  applying only non- medicated make-up. 
 
ADDITIONAL  REMINDERS:  
• Store study product at Room Temperature 20 to 25°C (68 to 77°F). Excursions permitted  
between 15 to 30°C (59 to 86°F).  Do not  freeze, refrigerate or expose to extreme 
temperature.”  
• Avoid contact  with  the eyes, inside the nose, mouth and all  mucous membranes.  
• Caution: This product contains  benzoyl peroxide which  can bleach  hair or colored  fabric.  
• THE PRODUCT SHOULD BE USED ONLY BY THE PERSON FOR WHOM IT WAS  
PRESCRIBED and it should be kept out of the reach of children or others of limited  
capacity  to read or understand. 
• Pumps of study product must be returned to the study facility,  even  if they  are empty. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  78 of 85  
 • If you miss any doses, at your next visit inform  the study doctor of the date(s)  of the missed  
dose(s).  Please record  all doses on the Diary  Card  provided to you; indicate  reason  for any 
missed dose on the Diary Card.  
• Throughout the study, continue to use on your face only the same  cleanser  provided by the 
doctor for this study. 
• If you use a moisturizer  and/or sunscreen, you must use the one provided by the doctor for 
this study. 
• On the day of your study visit,  do not apply  moisturizer/sunscreen,  or make- up. 
• You must not use any other treatment for your rosacea while you are participating in this  
study. 
• Avoid unnecessary sun exposure and tanning booths. When sun exposure cannot be  
avoided, use the approved moisturizer/sunscreen and wear a wide -brimmed hat.  
It is important that you inform  the study site about any medications  (i.e., prescriptions, over-the-
counter medications, street drugs, or herbal medications) that you have taken during the study. 
Bring this sheet, your updated Diary Card, and your study product pump with you to every study  
visit.  
 
STUDY VISIT  SCHEDULE:  
 
VISIT  2: Baseline Day 1 
Date:  Time: 
VISIT 3:  Week 2,  Day  15 
Date:  Time: 
VISIT 4:  Week 4,  Day  29 
Date:  Time: 
VISIT  5: Week 8,  Day  57 
Date:  Time: 
VISIT  6: Week 12, Day  85 
Date:  Time: 
 
 
Thank you for following these instructions. 
SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  79 of 85  
 APPENDIX  2: PRO  – PAPSS   

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  80 of 85  
 APPENDIX  3: PRO  – PAPI  

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  81 of 85  
 APPENDIX  4: PRO  – PGI-S 
 
 
 

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  82 of 85  
 APPENDIX  5: PRO  – PGI-C 
 
 
 

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  83 of 85  
 APPENDIX  6: PRO  – PGI-TS 
 
 
 
 

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  84 of 85  
 APPENDIX  7: PRO  – PGI-SE  
 
 
 

SGT -54-01, Ver 4.0 
CONFIDENTIAL  Page  85 of 85  
 APPENDIX  8: ROSACEA QUALITY OF LIFE  QUESTIONNAIRE  
(ROSAQOL) 
 
